<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:51:33Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:3895324" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:3895324</identifier><datestamp>2014-01-21</datestamp><setSpec>elsevierwt</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Lancet Neurol</journal-id>
      <journal-id journal-id-type="iso-abbrev">Lancet Neurol</journal-id>
      <journal-title-group>
        <journal-title>Lancet Neurology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1474-4422</issn>
      <issn pub-type="epub">1474-4465</issn>
      <publisher>
        <publisher-name>Lancet Pub. Group</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC3895324</article-id>
      <article-id pub-id-type="pmcid">PMC3895324</article-id>
      <article-id pub-id-type="pmc-uid">3895324</article-id>
      <article-id pub-id-type="pmid">24291220</article-id>
      <article-id pub-id-type="publisher-id">S1474-4422(13)70265-5</article-id>
      <article-id pub-id-type="doi">10.1016/S1474-4422(13)70265-5</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>The genetic basis of DOORS syndrome: an exome-sequencing study</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Campeau</surname>
            <given-names>Philippe M</given-names>
          </name>
          <degrees>MD</degrees>
          <xref rid="aff1" ref-type="aff">a</xref>
          <xref rid="fn1" ref-type="fn">â </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kasperaviciute</surname>
            <given-names>Dalia</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref rid="aff2" ref-type="aff">b</xref>
          <xref rid="fn1" ref-type="fn">â </xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lu</surname>
            <given-names>James T</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref rid="aff3" ref-type="aff">c</xref>
          <xref rid="aff4" ref-type="aff">d</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Burrage</surname>
            <given-names>Lindsay C</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref rid="aff1" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Choel</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref rid="aff5" ref-type="aff">e</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hori</surname>
            <given-names>Mutsuki</given-names>
          </name>
          <degrees>MD</degrees>
          <xref rid="aff6" ref-type="aff">f</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Powell</surname>
            <given-names>Berkley R</given-names>
          </name>
          <degrees>MD</degrees>
          <xref rid="aff7" ref-type="aff">g</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stewart</surname>
            <given-names>Fiona</given-names>
          </name>
          <degrees>MBBS</degrees>
          <xref rid="aff8" ref-type="aff">h</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>FÃ©lix</surname>
            <given-names>TÃªmis Maria</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref rid="aff9" ref-type="aff">i</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>van den Ende</surname>
            <given-names>Jenneke</given-names>
          </name>
          <degrees>MD</degrees>
          <xref rid="aff10" ref-type="aff">j</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wisniewska</surname>
            <given-names>Marzena</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref rid="aff11" ref-type="aff">k</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kayserili</surname>
            <given-names>HÃ¼lya</given-names>
          </name>
          <degrees>MD</degrees>
          <xref rid="aff12" ref-type="aff">l</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rump</surname>
            <given-names>Patrick</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref rid="aff13" ref-type="aff">m</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nampoothiri</surname>
            <given-names>Sheela</given-names>
          </name>
          <degrees>MSc</degrees>
          <xref rid="aff14" ref-type="aff">n</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Aftimos</surname>
            <given-names>Salim</given-names>
          </name>
          <degrees>MD</degrees>
          <xref rid="aff15" ref-type="aff">o</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mey</surname>
            <given-names>Antje</given-names>
          </name>
          <degrees>MD</degrees>
          <xref rid="aff16" ref-type="aff">p</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nair</surname>
            <given-names>Lal D V</given-names>
          </name>
          <degrees>MD</degrees>
          <xref rid="aff17" ref-type="aff">q</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Begleiter</surname>
            <given-names>Michael L</given-names>
          </name>
          <degrees>MSc</degrees>
          <xref rid="aff18" ref-type="aff">r</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>De Bie</surname>
            <given-names>Isabelle</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref rid="aff19" ref-type="aff">s</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Meenakshi</surname>
            <given-names>Girish</given-names>
          </name>
          <degrees>MBBS</degrees>
          <xref rid="aff20" ref-type="aff">t</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Murray</surname>
            <given-names>Mitzi L</given-names>
          </name>
          <degrees>MD</degrees>
          <xref rid="aff21" ref-type="aff">u</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Repetto</surname>
            <given-names>Gabriela M</given-names>
          </name>
          <degrees>MD</degrees>
          <xref rid="aff22" ref-type="aff">v</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Golabi</surname>
            <given-names>Mahin</given-names>
          </name>
          <degrees>MD</degrees>
          <xref rid="aff23" ref-type="aff">w</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Blair</surname>
            <given-names>Edward</given-names>
          </name>
          <degrees>MD</degrees>
          <xref rid="aff24" ref-type="aff">x</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Male</surname>
            <given-names>Alison</given-names>
          </name>
          <degrees>MD</degrees>
          <xref rid="aff25" ref-type="aff">y</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Giuliano</surname>
            <given-names>Fabienne</given-names>
          </name>
          <degrees>MD</degrees>
          <xref rid="aff26" ref-type="aff">z</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kariminejad</surname>
            <given-names>Ariana</given-names>
          </name>
          <degrees>MD</degrees>
          <xref rid="aff27" ref-type="aff">aa</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Newman</surname>
            <given-names>William G</given-names>
          </name>
          <xref rid="aff28" ref-type="aff">ab</xref>
          <xref rid="aff29" ref-type="aff">ac</xref>
          <xref rid="aff30" ref-type="aff">ad</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bhaskar</surname>
            <given-names>Sanjeev S</given-names>
          </name>
          <xref rid="aff28" ref-type="aff">ab</xref>
          <xref rid="aff29" ref-type="aff">ac</xref>
          <xref rid="aff30" ref-type="aff">ad</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dickerson</surname>
            <given-names>Jonathan E</given-names>
          </name>
          <xref rid="aff28" ref-type="aff">ab</xref>
          <xref rid="aff29" ref-type="aff">ac</xref>
          <xref rid="aff30" ref-type="aff">ad</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kerr</surname>
            <given-names>Bronwyn</given-names>
          </name>
          <xref rid="aff28" ref-type="aff">ab</xref>
          <xref rid="aff29" ref-type="aff">ac</xref>
          <xref rid="aff30" ref-type="aff">ad</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Banka</surname>
            <given-names>Siddharth</given-names>
          </name>
          <xref rid="aff28" ref-type="aff">ab</xref>
          <xref rid="aff29" ref-type="aff">ac</xref>
          <xref rid="aff30" ref-type="aff">ad</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Giltay</surname>
            <given-names>Jacques C</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref rid="aff31" ref-type="aff">ae</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wieczorek</surname>
            <given-names>Dagmar</given-names>
          </name>
          <degrees>MD</degrees>
          <xref rid="aff32" ref-type="aff">af</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tostevin</surname>
            <given-names>Anna</given-names>
          </name>
          <degrees>MSc</degrees>
          <xref rid="aff2" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wiszniewska</surname>
            <given-names>Joanna</given-names>
          </name>
          <degrees>MD</degrees>
          <xref rid="aff1" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cheung</surname>
            <given-names>Sau Wai</given-names>
          </name>
          <degrees>Prof</degrees>
          <degrees>PhD</degrees>
          <xref rid="aff1" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hennekam</surname>
            <given-names>Raoul C</given-names>
          </name>
          <degrees>Prof</degrees>
          <degrees>PhD</degrees>
          <xref rid="aff33" ref-type="aff">ag</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gibbs</surname>
            <given-names>Richard A</given-names>
          </name>
          <degrees>Prof</degrees>
          <degrees>PhD</degrees>
          <xref rid="aff3" ref-type="aff">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>Brendan H</given-names>
          </name>
          <degrees>Prof</degrees>
          <degrees>PhD</degrees>
          <email>blee@bcm.edu</email>
          <xref rid="aff1" ref-type="aff">a</xref>
          <xref rid="aff34" ref-type="aff">ah</xref>
          <xref rid="cor1" ref-type="corresp">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sisodiya</surname>
            <given-names>Sanjay M</given-names>
          </name>
          <degrees>Prof</degrees>
          <degrees>PhD</degrees>
          <email>s.sisodiya@ucl.ac.uk</email>
          <xref rid="aff2" ref-type="aff">b</xref>
          <xref rid="aff35" ref-type="aff">ai</xref>
          <xref rid="cor2" ref-type="corresp">**</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>a</label>Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA</aff>
      <aff id="aff2"><label>b</label>Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK</aff>
      <aff id="aff3"><label>c</label>Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA</aff>
      <aff id="aff4"><label>d</label>Department of Structural and Computational Biology and Molecular Biophysics, Baylor College of Medicine, Houston, TX, USA</aff>
      <aff id="aff5"><label>e</label>Department of Pharmacology, Baylor College of Medicine, Houston, TX, USA</aff>
      <aff id="aff6"><label>f</label>Department of Pediatrics, Toyohashi Municipal Hospital, Toyohashi, Aichi, Japan</aff>
      <aff id="aff7"><label>g</label>Children's Hospital Central California, Madera, California, USA</aff>
      <aff id="aff8"><label>h</label>Genetics Service, Belfast City Hospital, Belfast, Ireland</aff>
      <aff id="aff9"><label>i</label>Medical Genetics Service, Clinical Hospital of Porto Alegre, Porto Alegre, Brazil</aff>
      <aff id="aff10"><label>j</label>Department of Medical Genetics, University Hospital Antwerp, 2650 Antwerp, Belgium</aff>
      <aff id="aff11"><label>k</label>Department of Medical Genetics, PoznaÃ± University of Medical Sciences, PoznaÃ±, Poland</aff>
      <aff id="aff12"><label>l</label>Medical Genetics Department, Istanbul Medical Faculty, Istanbul University, Turkey</aff>
      <aff id="aff13"><label>m</label>Department of Genetics, University of Groningen, Groningen, Netherlands</aff>
      <aff id="aff14"><label>n</label>Department of Pediatric Genetics, Amrita Institute of Medical Sciences and Research Centre, Kerala, India</aff>
      <aff id="aff15"><label>o</label>Genetic Health Service New ZealandâNorthern Hub, Auckland City Hospital, Auckland, New Zealand</aff>
      <aff id="aff16"><label>p</label>Pediatric Neurology, Braunschweig Hospital, Braunschweig, Germany</aff>
      <aff id="aff17"><label>q</label>Department of Pediatrics, Saveetha Medical College and Hospital, Saveetha University, Chennai, Tamil Nadu, 600077, India</aff>
      <aff id="aff18"><label>r</label>Division of Genetics, Children's Mercy Hospitals and Clinics and the University of Missouri-Kansas City School of Medicine, Kansas City, MO, USA</aff>
      <aff id="aff19"><label>s</label>Department of Medical Genetics, Montreal Children's Hospital, McGill University Health Center, Quebec, Canada</aff>
      <aff id="aff20"><label>t</label>Department of Pediatrics, NKP Salve Institute of Medical Sciences and Lata Mangeshkar Hospital, Maharashtra, India</aff>
      <aff id="aff21"><label>u</label>University of Washington Medical Center, Seattle, WA, USA</aff>
      <aff id="aff22"><label>v</label>Center for Human Genetics, Facultad de Medicina, ClÃ­nica Alemana-Universidad del Desarrollo, Santiago, Chile</aff>
      <aff id="aff23"><label>w</label>Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA</aff>
      <aff id="aff24"><label>x</label>Department of Clinical Genetics, Churchill Hospital, Oxford, UK</aff>
      <aff id="aff25"><label>y</label>Clinical Genetics Department, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK</aff>
      <aff id="aff26"><label>z</label>Centre RÃ©fÃ©rence Anomalie DÃ©veloppement et Syndromes Malformatifs, Centre Hospitalier Universitaire de Nice, France</aff>
      <aff id="aff27"><label>aa</label>Kariminejad-Najmabadi Pathology and Genetics Center, Tehran, Iran</aff>
      <aff id="aff28"><label>ab</label>Manchester Centre for Genomic Medicine, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK</aff>
      <aff id="aff29"><label>ac</label>Manchester Centre for Genomic Centre for Genetic Medicine, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK</aff>
      <aff id="aff30"><label>ad</label>St Mary's Hospital, Manchester Academic Health Science Centre, Manchester, UK</aff>
      <aff id="aff31"><label>ae</label>Department of Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands</aff>
      <aff id="aff32"><label>af</label>Institut fÃ¼r Humangenetik, University of Duisburg-Essen, University Hospital Essen, Essen, Germany</aff>
      <aff id="aff33"><label>ag</label>Department of Pediatrics and Translational Genetics, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands</aff>
      <aff id="aff34"><label>ah</label>Howard Hughes Medical Institutes, Houston, TX, USA</aff>
      <aff id="aff35"><label>ai</label>Epilepsy Society, Buckinghamshire, UK</aff>
      <author-notes>
        <corresp id="cor1"><label>*</label>Correspondence to: Prof Brendan H Lee, Howard Hughes Medical Institute, Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, R814-MS225, Houston, TX 77030, USA <email>blee@bcm.edu</email></corresp>
        <corresp id="cor2"><label>**</label>Prof Sanjay M Sisodiya, Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, Queen Square, London, WC1N 3BG, UK <email>s.sisodiya@ucl.ac.uk</email></corresp>
        <fn id="fn1">
          <label>â </label>
          <p>These authors contributed equally</p>
        </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <day>1</day>
        <month>1</month>
        <year>2014</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was
					based on <pub-date pub-type="ppub">.-->
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2014</year>
      </pub-date>
      <volume>13</volume>
      <issue>1</issue>
      <fpage>44</fpage>
      <lpage>58</lpage>
      <permissions>
        <copyright-statement>Â© 2014 Campeau et al. Open Access article distributed under the terms of CC BY</copyright-statement>
        <copyright-year>2014</copyright-year>
        <license>
          <license-p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract>
        <title>Summary</title>
        <sec>
          <title>Background</title>
          <p>Deafness, onychodystrophy, osteodystrophy, mental retardation, and seizures (DOORS) syndrome is a rare autosomal recessive disorder of unknown cause. We aimed to identify the genetic basis of this syndrome by sequencing most coding exons in affected individuals.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>Through a search of available case studies and communication with collaborators, we identified families that included at least one individual with at least three of the five main features of the DOORS syndrome: deafness, onychodystrophy, osteodystrophy, intellectual disability, and seizures. Participants were recruited from 26 centres in 17 countries. Families described in this study were enrolled between Dec 1, 2010, and March 1, 2013. Collaborating physicians enrolling participants obtained clinical information and DNA samples from the affected child and both parents if possible. We did whole-exome sequencing in affected individuals as they were enrolled, until we identified a candidate gene, and Sanger sequencing to confirm mutations. We did expression studies in human fibroblasts from one individual by real-time PCR and western blot analysis, and in mouse tissues by immunohistochemistry and real-time PCR.</p>
        </sec>
        <sec>
          <title>Findings</title>
          <p>26 families were included in the study. We did exome sequencing in the first 17 enrolled families; we screened for <italic>TBC1D24</italic> by Sanger sequencing in subsequent families. We identified <italic>TBC1D24</italic> mutations in 11 individuals from nine families (by exome sequencing in seven families, and Sanger sequencing in two families). 18 families had individuals with all five main features of DOORS syndrome, and <italic>TBC1D24</italic> mutations were identified in half of these families. The seizure types in individuals with <italic>TBC1D24</italic> mutations included generalised tonic-clonic, complex partial, focal clonic, and infantile spasms. Of the 18 individuals with DOORS syndrome from 17 families without <italic>TBC1D24</italic> mutations, eight did not have seizures and three did not have deafness. In expression studies, some mutations abrogated <italic>TBC1D24</italic> mRNA stability. We also detected <italic>Tbc1d24</italic> expression in mouse phalangeal chondrocytes and calvaria, which suggests a role of TBC1D24 in skeletogenesis.</p>
        </sec>
        <sec>
          <title>Interpretation</title>
          <p>Our findings suggest that mutations in <italic>TBC1D24</italic> seem to be an important cause of DOORS syndrome and can cause diverse phenotypes. Thus, individuals with DOORS syndrome without deafness and seizures but with the other features should still be screened for <italic>TBC1D24</italic> mutations. More information is needed to understand the cellular roles of TBC1D24 and identify the genes responsible for DOORS phenotypes in individuals who do not have a mutation in <italic>TBC1D24</italic>.</p>
        </sec>
        <sec>
          <title>Funding</title>
          <p>US National Institutes of Health, the CIHR (Canada), the NIHR (UK), the Wellcome Trust, the Henry Smith Charity, and Action Medical Research.</p>
        </sec>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec id="cesec10">
      <title>Introduction</title>
      <p>Deafness, onychodystrophy, osteodystrophy, and mental retardation (DOOR or DOORS) syndrome (OMIM 220500) is a rare autosomal recessive disorder of unknown cause. Ronald Cantwell first described DOOR syndrome in 1975,<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> noting that a few similarly affected individuals had been reported prior to that date. Qazi and colleagues suggested changing the name to DOORS syndrome to account for the presence of seizures in most individuals,<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> and we use this term in this Article. The case reports of 32 affected individuals were reviewed by James and colleagues in 2007,<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> and five others have been published since that report.<xref rid="bib4 bib5 bib6 bib7 bib8" ref-type="bibr"><sup>4â8</sup></xref> Seizures, present in most patients with DOORS syndrome, usually start in the first year of life. They occasionally occur with increasing frequency or severity and are sometimes refractory to antiepileptic drugs. The seizures are often generalised tonic-clonic, but myoclonic, partial, and absence seizures also occur.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> Neurological involvementâapart from the epilepsy, intellectual disability, and profound sensorineural hearing loss in most affected individualsâincludes occasional optic neuropathy, visual impairment, peripheral neuropathy, and abnormalities on brain MRI. The onycho-osteodystrophy affects a patient's hands and feet equally. Small or absent nails and hypoplastic terminal phalanges are seen in most individuals. A triphalangeal thumb is present in a third of affected individuals. A large base of the nose and a bulbous nose are the most common facial dysmorphisms. Cranial anomalies include microcephaly in a third of individuals and a narrow bifrontal diameter in two thirds. The rarity of DOORS syndrome, the absence of any single pathognomonic feature, the substantial clinical variability (including malformations of the brain, eyes, heart, kidneys, skeletal system, adrenal glands, and genitalia<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref>), and features shared with other syndromes, make its clinical diagnosis challenging. In turn, such difficulties hinder understanding of its true prevalence and prognosis, limiting the possibility of accurate counselling. Better diagnostic measures are therefore needed.</p>
      <p>For rare diseases in general, the identification of genetic causes has been a productive approach to improved understanding and more specific diagnosis. The genetic cause of DOORS syndrome is unknown.<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref> Strategies to identify disease-causing genes in inherited diseases have changed with the development and availability of new technologies. For example, in epilepsy, channelopathies were identified in the 1990s mostly with positional cloning and candidate gene sequencing.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> Next-generation sequencing, such as whole-exome sequencing, has accelerated the pace of the identification of epilepsy-associated genes. For instance, <italic>PPRT2</italic> mutations were identified initially in paroxysmal kinesigenic dyskinesia, and are also seen in infantile seizures and febrile seizures.<xref rid="bib11 bib12" ref-type="bibr"><sup>11,12</sup></xref> In the past year, <italic>DEPDC5</italic> mutations have been identified in various dominantly-inherited familial focal epilepsies.<xref rid="bib13 bib14" ref-type="bibr"><sup>13,14</sup></xref> The precise role of each protein in the CNS has not been established. In a cohort of patients with a clinical diagnosis of DOORS syndrome, we sought to identify the genetic basis by whole-exome sequencing, aiming thus to provide improved diagnostic resolution and, eventually, a better understanding of the disorder.</p>
    </sec>
    <sec sec-type="methods" id="cesec20">
      <title>Methods</title>
      <sec id="cesec30">
        <title>Participants</title>
        <p>We contacted previous collaborators and physicians who had published case reports of individuals with DOORS syndrome. Patients were from 26 centres in 17 countries. Between Dec 1, 2010, and March 1, 2013, we enrolled identified individuals with DOORS syndrome who were assessed by clinical geneticists and had at least three of the five following features: deafness, abnormal nails or digits on the hands or feet, developmental delay or intellectual disability (previously known as mental retardation), and seizures.</p>
        <p>Families were excluded if the parents could not be contacted for consent or if DNA could not be obtained from the affected individual. Further exclusion criteria were autosomal dominant inheritance and the absence of both intellectual disability and seizures, criteria that have been used elsewhere.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> A clinical questionnaire was completed by the collaborating physician. DNA was collected from the affected individual and both parents if possible.</p>
        <p>A parent provided written informed consent on behalf of the affected individual. We did this study with the approval of the institutional ethics review boards of the Baylor College of Medicine (TX, USA), of University College London (London, UK), of the University of Amsterdam (Amsterdam, Netherlands), and of the University of Manchester (Manchester, UK).</p>
      </sec>
      <sec sec-type="methods" id="cesec40">
        <title>Procedures</title>
        <p>A detailed description of the method for exome sequencing and data analysis is provided in the <xref rid="sec1" ref-type="sec">appendix</xref>. (p 2) Briefly, genomic DNA was fragmented, enriched for coding regions, and sequenced on an Illumina HiSeq 2000 instrument (Illumina; San Diego, CA, USA). Reads were aligned to the reference human genome, and analysed for variations from the reference. The variants were filtered to keep only rare or novel variants, and these variants were annotated for conservation data, predicted effect of the variant, variant frequency in various databases such as the Exome Variant Server, gene expression pattern, function of the gene, and phenotypes in mice and human beings. Our variant detection and filtering method was deliberately sensitive but not specific, meaning that there are multiple false-positive variants identified. False-positive variant calls can be due to artifacts introduced by the next-generation technology used,<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> poor coverage in GC-rich regions, bases missed by next-generation sequencing because of homopolymers or dinucleotide repeats, or mapping difficulties because of gene homologues or paralogues. The most efficient method to remove these false-positive variants is to visualise alignment files (binary alignment map files), using Broad Institute's <ext-link ext-link-type="uri" xlink:href="http://www.broadinstitute.org/igv" id="interrefs10">IGV viewer</ext-link> from affected individuals and compare them to variant files from unaffected individuals or individuals with disorders unrelated to DOORS syndrome (exomes published elsewhere<xref rid="bib16 bib17 bib18 bib19 bib20" ref-type="bibr"><sup>16â20</sup></xref>), which we did after restricting the candidate gene list by focusing initially on genes with an autosomal recessive inheritance pattern (one homozygous mutation or two heterozygous mutations).</p>
        <p>We did single nucleotide polymorphism (SNP) analysis with the Illumina Infinium HD assay platform using HumanOmni1-Quad BeadChip (Illumina) according to the manufacturer's instructions, and analysed data using Illumina's GenomeStudio to look for insertions, deletions, and regions of homozygosity as well as haplotypes shared by affected siblings.</p>
        <p>Primers used for Sanger sequencing of the genomic DNA that encodes the complete coding sequence of <italic>TBC1D24</italic> variant 1 (NCBI CCDS ID#55980.1) were generated with an online software <ext-link ext-link-type="uri" xlink:href="http://ihg.gsf.de/ihg/ExonPrimer.html" id="interrefs20">ExonPrimer</ext-link> (see <xref rid="sec1" ref-type="sec">appendix p 6</xref> for a list of primers). We generated amplicons with 10 ng of genomic DNA using TaqMan polymerase (ABI, Life Technologies, Carlsbad, CA, USA) with the manufacturer's protocol with an annealing temperature of 55Â°C and an amplification of 1 min. Products were sequenced by the Sanger method using the same primers, at Beckman Coulter Genomics (Danvers, MA, USA). We analysed resulting chromatograms by comparing the GenBank file for the RefSeq sequence of <italic>TBC1D24</italic> using Sequencher (version 4.8; Gene Codes Corporation, Ann Arbor, MI, USA).</p>
        <p>We also did real-time PCR. We grew fibroblasts in Dulbecco's Modified Eagle's Medium with 10% fetal bovine serum, 1Â·5 mM glutamine, 100 IU/mL penicillin, and 50 Î¼g/mL streptomycin (Invitrogen, Grand Island, NY, USA). Mouse tissues were from C57BL/6J wildtype mice. RNA was extracted from fibroblasts or mouse tissues using TRIzol and GlycoBlue, then cDNA was synthesised using SuperScript III First-Strand Synthesis Kit according to the manufacturer's instructions (all from Invitrogen). We did quantitative real-time PCR using the primers listed in the <xref rid="sec1" ref-type="sec">appendix (p 6)</xref>, the FastStart DNA Master SYBR Green reagent, and a LightCycler instrument using an annealing temperature of 65Â°C according to the manufacturer's protocol (both from Roche NimbleGen, Madison, WI, USA).</p>
        <p>Details of immunohistochemistry and western blotting methods used are in the <xref rid="sec1" ref-type="sec">appendix (pp 2â3)</xref>. We generated the structural model of human <italic>TBC1D24</italic> with Phyre2, an online software,<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> based on the crystal structures of the TBC domain of TBC1D1 and TBC1D4 and the TBC, LysM, Domain catalytic (TLDc) domain of the zebrafish Oxr2 protein.<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref> We made the three-dimentional figure using Pymol (version 1.6).</p>
      </sec>
      <sec id="cesec50">
        <title>Statistical analyses</title>
        <p>We calculated differences in mRNA expression in fibroblasts using the Student's <italic>t</italic> test. For the expression in different mouse tissues, we did a Kruskal-Wallis one-way ANOVA on ranks, as well as a multiple comparison procedure using Dunnett's method. We used SigmaPlot (version 11.0) for all statistical analyses.</p>
      </sec>
      <sec id="cesec60">
        <title>Role of the funding source</title>
        <p>The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="cesec70">
      <title>Results</title>
      <p>We identified 30 families, of which four were excluded from the study: two families that could not be re-contacted for informed consent; one family in which the affected child had died and DNA was not available; and one family in which the phenotype corresponded to dominant deafness-onychodystrophy (DDOD; OMIM 124480). We did exome sequencing in the first 17 enrolled families and SNP arrays in three of these families with consanguinity or more than one affected child. Because sequencing and data preparation takes 3â5 months, we analysed exomes and SNP arrays after sequencing was completed in 15 families (<xref rid="fig1" ref-type="fig">figure 1</xref>). Of genes with rare or novel protein-affecting variants (compared with the frequency in the control groupâie, the 6503 exomes in the Exome Variant Server), 6645 genes had at least one rare or novel variant in at least one of fifteen samples. To restrict the list of candidate genes, we applied filtering based initially on an autosomal recessive inheritance, analysed genes mutated in several samples, and removed the false-positive variants (<xref rid="sec1" ref-type="sec">appendix p7</xref>). We visually compared the DOORS syndrome exome alignments to other exomes previously acquired for unrelated disorders,<xref rid="bib16 bib17 bib18 bib19 bib20" ref-type="bibr"><sup>16â20</sup></xref> focusing initially on genes with a recessive inheritance pattern (one homozygous mutation or two heterozygous mutations) and variants identified in the highest number of affected individuals. Most variants in genes identified in most exomes by our annotation pipeline proved to be false-positive variants on visualisation and comparison with control exomes (<xref rid="sec1" ref-type="sec">appendix p 7</xref>).</p>
      <p>We identified either homozygous or compound heterozygous mutations in <italic>TBC1D24</italic> (RefSeq# NM_001199107.1) in affected individuals in six of the initial 15 families in which we did exome sequencing (<xref rid="tbl1" ref-type="table">table 1</xref>). All mutations were novel except for the frameshift mutation, seen in the heterozygous carrier state in two of 6118 individuals sequenced for that region in the June, 2013, release of the Exome Variant Server (EVS-v.0.0.20). This server provides variant frequency data for multiple exome studies done mostly in adults with various heart and lung diseases and controls, and individual phenotypes are not available. In view of the facts that mutations in this gene have been identified as the cause of some epilepsies,<xref rid="bib23 bib24 bib25 bib26 bib27" ref-type="bibr"><sup>23â27</sup></xref> that seizures are common in people with DOORS syndrome, and that all mutations we identified were novel or very rare and in some cases truncating, this gene was the most suitable candidate in our cohort. We completed exome sequencing (followed by Sanger validation) in two individuals for whom exome sequencing was already started, and did Sanger sequencing of <italic>TBC1D24</italic> only in the nine subsequently enrolled families (see <xref rid="sec1" ref-type="sec">appendix p 6</xref> for primers). We identified three more families with <italic>TBC1D24</italic> mutations, one through additional exome sequencing and two by Sanger sequencing, totalling 11 affected individuals from nine families with confirmed mutations in the cohort of 26 families affected by DOORS syndrome (see <xref rid="tbl1" ref-type="table">table 1</xref> for the <italic>TBC1D24</italic> mutations identified and the <xref rid="sec1" ref-type="sec">appendix p 4</xref> for analyses done on each family). Annotations for all <italic>TBC1D24</italic> variants (from DOORS syndrome, the other associated epileptic disorders, and the Exome Variant Server), including population frequency, conservation scores and PolyPhen2 scores are in the <xref rid="sec1" ref-type="sec">appendix (p 8)</xref>. Collectively, other coding variants in <italic>TBC1D24</italic> were seen in the heterozygous state in 343 (5%) of 6503 of the Exome Variant Server cohort.</p>
      <p>We saw a wide variety of seizure types in our cohort of individuals with <italic>TBC1D24</italic> mutations, including generalised tonic-clonic, complex partial, focal clonic seizures, and infantile spasms. <xref rid="tbl2 tbl3" ref-type="table">Tables 2 and 3</xref> list the clinical features of individuals with and without <italic>TBC1D24</italic> mutations. <xref rid="fig2" ref-type="fig">Figure 2</xref> shows photographs of the face, hands, feet, and radiographs. The mutations are listed in <xref rid="tbl1" ref-type="table">table 1</xref> and shown in <xref rid="fig3" ref-type="fig">figure 3</xref>. The conservation of the affected residues and nucleotides is given in the <xref rid="sec1" ref-type="sec">appendix (p 17)</xref>. In families with <italic>TBC1D24</italic> mutations and consanguinity, the mutations were homozygous and <italic>TBC1D24</italic> was in a region of homozygosity as identified by SNP array or homozygosity mapping from exome data. The regions of homozygosity are given in the <xref rid="sec1" ref-type="sec">appendix (p 11)</xref>.</p>
      <p>Because of the recessive nature of the disease and the presence of mutations predicted to lead to premature protein termination, we proposed that the mutations cause a loss of TBC1D24 function. We assessed this hypothesis in fibroblasts from a biopsy previously done for clinical reasons in individual 3, who was compound heterozygote for a splice site mutation and a frameshift mutation in <italic>trans</italic>. This frameshift mutation, because it is not in the last exon, is predicted to lead to nonsense-mediated decay (NMD) of the mRNA.<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> The splice donor mutation after exon five, because it is located five nucleotides away from a splice site (1206+5GâA), might or might not affect splicing efficiency. If it affects splicing efficiency, the mutation would lead to an aberrant protein-encoding mRNA, thus engaging NMD. To test for NMD, we did real-time PCR (<xref rid="fig3" ref-type="fig">figure 3</xref>). <italic>TBC1D24</italic> mRNA concentrations in the fibroblasts from individual 3 were 5% (SE 1%) of the concentrations from three unaffected controls (Student's <italic>t</italic> test p=0Â·024), confirming that the mRNA from both alleles undergoes NMD and thus showing a loss of <italic>TBC1D24</italic> function. TBC1D24 protein from these fibroblasts could not be detected by western blot analysis (<xref rid="fig3" ref-type="fig">figure 3</xref>).</p>
      <p>We next assessed <italic>Tbc1d24</italic> tissue expression. <italic>Tbc1d24</italic> is known to be widely expressed, most highly in the brain (especially in pyramidal neurons), kidneys, and salivary and lacrimal glands.<xref rid="bib29 bib30" ref-type="bibr"><sup>29,30</sup></xref> In the brain, the regions with the highest expression levels are the hippocampus and the somatomotor areas of the isocortex (<xref rid="sec1" ref-type="sec">appendix p 13</xref>). Using an antibody against TBC1D24, we studied expression in digital chondrocytes, in view of the distal phalangeal hypoplasia in DOORS syndrome and the high expression seen in chondrocytes in the <ext-link ext-link-type="uri" xlink:href="http://www.proteinatlas.org/ENSG00000162065" id="interrefs30">Human Protein Atlas</ext-link>. Expression was high in the chondrocytes of the distal phalanges of the forelimbs (<xref rid="sec1" ref-type="sec">appendix p 19</xref>). Moreover, we assessed expression by real-time PCR in various newborn mouse tissues and noticed high expression in the calvarium (<xref rid="sec1" ref-type="sec">appendix p 19</xref>), which correlates well with the cranial shape phenotype and occasional cranial synostosis seen in affected individuals (<xref rid="tbl2" ref-type="table">table 2</xref>).</p>
      <p>TBC1D24 contains a TLDc domain and regulates Rab proteins. In our cohort, we identified no mutations in the other TLDc domain-containing genes by exome sequencing (<xref rid="sec1" ref-type="sec">appendix p 14</xref>). By homology modelling, the substitutions we identified did not seem to affect portions of the protein predicted to interact with the TLDc domain, nor were they in the region that typically interacts with GTP in other TBC proteins (<xref rid="fig3" ref-type="fig">figure 3</xref>). Because TBC1D24 regulates Rab proteins and because of clinical overlap between DOORS syndrome and Martsolf syndrome, we also assessed <italic>RAB3GAP2</italic>. No <italic>RAB3GAP2</italic> mutations were identified in families without <italic>TBC1D24</italic> mutations (<xref rid="sec1" ref-type="sec">appendix p 14</xref>). Moreover, in genetic locus mapping by SNP arrays, or homozygosity mapping from exome data in some families without <italic>TBC1D24</italic> mutations, we did not identify a mutated gene in common in these families (details on the regions identified are given in the <xref rid="sec1" ref-type="sec">appendix p 11</xref>). Analyses are ongoing to identify candidate genes with mutations in families following either a de novo dominant or a recessive inheritance pattern. Details on analysis in the ten exomes without <italic>TBC1D24</italic> mutations are given in the <xref rid="sec1" ref-type="sec">appendix (pp 15â16)</xref>.</p>
      <p>Some individuals without <italic>TBC1D24</italic> mutations had typical features of DOORS syndrome, including the more specific signs of triphalangeal thumbs and 2-oxoglutaric aciduria, and were clinically indistinguishable from those with <italic>TBC1D24</italic> mutations. This finding suggests genetic heterogeneity in DOORS syndrome. In the individuals without <italic>TBC1D24</italic> mutations, eight did not have seizures and three did not have deafness (including one without seizures or deafness) and some individuals had additional malformations (eg, Arnold-Chiari malformation), which suggests that our cohort might include some individuals with disorders that overlap with but are different from DOORS syndrome (<xref rid="tbl2" ref-type="table">table 2</xref>). All individuals with <italic>TBC1D24</italic> mutations had all five features making the DOORS acronym. If we stratify based on this strict definition of DOORS syndrome, <italic>TBC1D24</italic> mutations were seen in nine of 18 families.</p>
    </sec>
    <sec sec-type="discussion" id="cesec80">
      <title>Discussion</title>
      <p>We have identified mutations in <italic>TBC1D24</italic> as a probable cause of DOORS syndrome. Previously reported, but different, mutations in <italic>TBC1D24</italic> cause various epileptic syndromes. A homozygous Phe251Leu substitution in four siblings of an Arab-Israeli family caused focal epilepsy, dysarthria, mild to moderate intellectual disability, and cortical thickening with cerebellar atrophy and a strong signal in the ansiform lobule of the cerebellum on T2-weighted and fluid-attenuated inversion recovery MRI.<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> In an Italian family, compound heterozygous substitutions (Asp147His and Ala515Val) cause familial infantile myoclonic epilepsy (FIME [OMIM 605021]) in seven individuals with normal intellect and normal MRI, except for periventricular nodular heterotopia in one individual.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> A homozygous truncating mutation (969_970delGT, Ser324Thrfs*3) in exon 3 was identified in five Turkish individuals with a recessive form of myoclonic epilepsy with episodic dystonia, hemiparesis, autonomic signs, and lethargy.<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> The five Turkish individuals developed the following: chronic dystonia, progressive diffuse cerebral atrophy, and early death. Exon 3 is spliced out in isoform 2, which is expressed predominantly in non-neural tissues. Finally, two compound heterozygous substitutions (Phe229Ser and Cys156*) were identified in two siblings with familial malignant migrating partial seizures of infancy, with progressive diffuse atrophy of the grey matter sparing the posterior fossa and early death.<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> The diversity of seizure types seen in <italic>TBC1D24</italic>-associated epileptic syndromes and in DOORS syndrome is striking (<xref rid="tbl2" ref-type="table">table 2</xref>), and might point to a general epileptogenic mechanism. None of the patients in previous reports of <italic>TBC1D24</italic> mutations had digital anomalies or deafness, and none of the above mutations was identified in our DOORS syndrome cohort, showing a clear genotype-to-phenotype correlation. The reason why some mutations cause DOORS syndrome and others cause only epilepsy might lie partly in the way the mutations affect interaction patterns with protein partners. This idea will need to be investigated. Some genes implicated in epilepsy seem capable of causing a wide variety of types of epilepsy, with greater or fewer additional neuropsychiatric features, and others have been associated with brain malformations or complex dysmorphic syndromes.<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> However, phenotypic pleiotropy has rarely been reported to span the spectrum from seizures alone (eg, previous reports on <italic>TBC1D24</italic> mutations) to multi-systemic syndromic disorders such as DOORS syndrome. These emerging findings of both genotype-phenotype complexity and genetic pleiotropy lend support to the view that, with accumulating mutational data, the fuller coverage afforded by exome (or genome) sequencing might be more useful than targeted gene panels in clinical practice.</p>
      <p>Five of the families with DOORS syndrome in our study have substitutions affecting the arginine at position 242, and two have substitutions affecting the arginine at position 40, suggesting that these residues are crucial in TBC1D24 function. Both are in a CpG island and affect CG dinucleotides. CpG nucleotides are more mutation-prone, which might explain mutation recurrence in individuals of different ethnic origins. Two patients also shared another recurrent mutation unique to DOORS (His336Glnfs*12).</p>
      <p>TBC1D24 is a member of the Tre2âBub2âCdc16 (TBC) domain-containing RAB-specific GTPase-activating proteins, which coordinate Rab proteins and other GTPases for the proper transport of intracellular vesicles. TBC1D24 is the only TBC/RabGAP with a TLDc domain, which is thought to be involved in oxidative stress resistance and to have catalytic activity for unknown substrates.<xref rid="bib32 bib33" ref-type="bibr"><sup>32,33</sup></xref> The TLDc domain is also seen in the proteins encoded by the human genes <italic>OXR1</italic>, <italic>NCOA7</italic>, <italic>KIAA1609</italic>, and <italic>C20orf118</italic>, which do not share known functions. Mice without <italic>Oxr1</italic> have oxidative stress-induced neurodegeneration,<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref> which suggests a possible link with the neurodegeneration seen in some individuals with <italic>TBC1D24</italic> mutations.<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> We saw no mutations in other TLDc domain encoding genes in this study. Several diseases have been associated with other aberrant Rab proteins and Rab-associated proteins. Some clinical overlap exists between DOORS syndrome and Martsolf syndrome (caused by mutations in <italic>RAB3GAP2</italic> gene [OMIM 212720]; shared aspects include seizures, intellectual disability, abnormal toenails, and short phalanges), and other syndromes. We identified no mutations in <italic>RAB3GAP2</italic>.</p>
      <p>Further research is needed to establish the precise role of TBC1D24 not only in the nervous system, but also in the skeletal system and other systems affected in DOORS syndrome. In <italic>Caenorhabditis elegans</italic>, C31H2.1 (a <italic>TBC1D24</italic> orthologue) was implicated in synaptic function by an RNAi screen.<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> In Drosophila, the orthologue Skywalker (Sky) enables endosomal trafficking in synaptic vesicles by facilitating GTP hydrolysis by Rab35, thus controlling synaptic vesicle rejuvenation and neurotransmitter release.<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref> Human TBC1D24 has low similarity to the Drosophila protein<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref> and neither possesses the arginine and glutamine residues (the so-called RQ fingers) that are crucial to catalyse GTP hydrolysis by Rab proteins.<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> Whether human TBC1D24 is able to also facilitate Rab protein-mediated GTP hydrolysis is not known.</p>
      <p>Our findings implicate defective vesicular trafficking as the possible basis of the complex phenotype in individuals with DOORS syndrome in view of findings from previous studies in other TBC proteins (<xref rid="box1" ref-type="boxed-text">panel</xref>). The seizure phenotype present in all individuals with <italic>TBC1D24</italic> mutations, and the studies in Drosophila, suggest a potential role for aberrant neurotransmitter release in the neurological manifestations of the disease. However, further studies in model organisms will be needed to study this in detail. At present, we are generating transgenic mice that will help us to assess these possibilities.</p>
      <p>Exome sequencing, although a powerful method to identify new genes linked to mendelian disorders, does have limitations. In a medical genetics clinical setting, exome sequencing has a diagnostic yield of 20â35%.<xref rid="bib38 bib39" ref-type="bibr"><sup>38,39</sup></xref> Some limitations are linked to the strategy of sequencing only exons: promoter mutations or deep intronic mutations affecting splicing will be missed. Other limitation are inherent to our study design; we did not analyse oligogenic inheritance (combination of one mutated allele in each of two or more genes) or synonymous exonic variants, which could be potentially deleterious. Finally, some limitations are technicalâeg, GC-rich regions are difficult to sequence and map, coverage can vary from sample to sample, and reads in genes that have paralogues or homologues can also be difficult to map to the reference genome. Future strategies to identify the causative genes in individuals with DOORS syndrome but without <italic>TBC1D24</italic> mutations could include consideration of oligogenic inheritance models, analysis of output for multiple different genes in the same pathway, an increase in enrolment and number of exomes or depth of exome sequencing, whole-genome sequencing, and analysis of exome data for copy-number variants.</p>
      <p>The phenotypic similarity between patients with and without <italic>TBC1D24</italic> mutations is highly suggestive of genetic heterogeneity in DOORS syndrome. In this study, individuals with <italic>TBC1D24</italic> mutations all had the five features of the DOORS acronym. However, other features were greatly variable, in terms of seizure types, pharmacoresponsiveness, brain-imaging abnormalities, cranial shape, 2-oxoglutaric aciduria, a triphalangeal thumb, and growth parameters. We saw a similar pattern in individuals without <italic>TBC1D24</italic> mutations: nine had the five features making the DOORS acronym; several had 2-oxoglutaric aciduria or a triphalangeal thumb. Further discussion on 2-oxoglutaric aciduria is provided in the <xref rid="sec1" ref-type="sec">appendix (p 20)</xref>.</p>
      <p>Through a combination of careful clinical phenotyping and exome sequencing, we have identified the molecular basis of DOORS syndrome in about a third of individuals included in our cohort, or in half of the 18 families in which affected individuals had the five features making the DOORS acronym. We suggest that individuals without deafness and seizures but with the other features should still be screened for <italic>TBC1D24</italic> mutations because we are only beginning to understand the genetic causation of DOORS syndrome: the discovery of <italic>TBC1D24</italic> mutations in a patient with an appropriate phenotype confirms the diagnosis of DOORS syndrome, but more cases need to be studied to establish the full clinical use of <italic>TBC1D24</italic> mutation testing. As has occurred with other rare diseases for which genetic analysis has elucidated the cause, we hope that this gene discovery can help galvanise clinical and scientific progress in understanding and treating DOORS syndrome.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="bib1">
        <label>1</label>
        <element-citation publication-type="journal" id="sbref10">
          <person-group person-group-type="author">
            <name>
              <surname>Cantwell</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>Congenital sensori-neural deafness associated with onycho-osteo dystrophy and mental retardation (D.O.O.R. syndrome)</article-title>
          <source>Humangenetik</source>
          <volume>26</volume>
          <year>1975</year>
          <fpage>261</fpage>
          <lpage>265</lpage>
          <pub-id pub-id-type="pmid">1132883</pub-id>
        </element-citation>
      </ref>
      <ref id="bib2">
        <label>2</label>
        <element-citation publication-type="journal" id="sbref20">
          <person-group person-group-type="author">
            <name>
              <surname>Qazi</surname>
              <given-names>QH</given-names>
            </name>
            <name>
              <surname>Nangia</surname>
              <given-names>BS</given-names>
            </name>
          </person-group>
          <article-title>Abnormal distal phalanges and nails, deafness, mental retardation, and seizure disorder: a new familial syndrome</article-title>
          <source>J Pediatr</source>
          <volume>104</volume>
          <year>1984</year>
          <fpage>391</fpage>
          <lpage>394</lpage>
          <pub-id pub-id-type="pmid">6707793</pub-id>
        </element-citation>
      </ref>
      <ref id="bib3">
        <label>3</label>
        <element-citation publication-type="journal" id="sbref30">
          <person-group person-group-type="author">
            <name>
              <surname>James</surname>
              <given-names>AW</given-names>
            </name>
            <name>
              <surname>Miranda</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Culver</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Golabi</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>DOOR syndrome: clinical report, literature review and discussion of natural history</article-title>
          <source>Am J Med Genet A</source>
          <volume>143A</volume>
          <year>2007</year>
          <fpage>2821</fpage>
          <lpage>2831</lpage>
          <pub-id pub-id-type="pmid">17994565</pub-id>
        </element-citation>
      </ref>
      <ref id="bib4">
        <label>4</label>
        <element-citation publication-type="journal" id="sbref40">
          <person-group person-group-type="author">
            <name>
              <surname>Girish</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mujawar</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Salodkar</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>DOOR syndrome</article-title>
          <source>Indian Pediatr</source>
          <volume>48</volume>
          <year>2011</year>
          <fpage>479</fpage>
          <lpage>481</lpage>
          <pub-id pub-id-type="pmid">21743113</pub-id>
        </element-citation>
      </ref>
      <ref id="bib5">
        <label>5</label>
        <element-citation publication-type="journal" id="sbref50">
          <person-group person-group-type="author">
            <name>
              <surname>Michalek</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Donaldson</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Abraham</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Anaesthetic management of an adult patient with DOOR syndrome: a case report</article-title>
          <source>Cases J</source>
          <volume>2</volume>
          <year>2009</year>
          <fpage>7593</fpage>
          <pub-id pub-id-type="pmid">19830001</pub-id>
        </element-citation>
      </ref>
      <ref id="bib6">
        <label>6</label>
        <element-citation publication-type="journal" id="sbref60">
          <person-group person-group-type="author">
            <name>
              <surname>Mihci</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Guney</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Velipasaoglu</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>DOOR (deafness, onychodystrophy, osteodystrophy, mental retardation) syndrome in one of the twins after conception with intracytoplasmic sperm injection</article-title>
          <source>Am J Med Genet A</source>
          <volume>146A</volume>
          <year>2008</year>
          <fpage>1483</fpage>
          <lpage>1485</lpage>
          <pub-id pub-id-type="pmid">18438887</pub-id>
        </element-citation>
      </ref>
      <ref id="bib7">
        <label>7</label>
        <element-citation publication-type="journal" id="sbref70">
          <person-group person-group-type="author">
            <name>
              <surname>Nomura</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Koyama</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Yokoyama</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Awaya</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yokochi</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>DOOR syndrome concomitant with non-convulsive status epilepticus and hyperintense cerebellar cortex on T2-weighted imaging</article-title>
          <source>Brain Dev</source>
          <volume>31</volume>
          <year>2009</year>
          <fpage>75</fpage>
          <lpage>78</lpage>
          <pub-id pub-id-type="pmid">18440741</pub-id>
        </element-citation>
      </ref>
      <ref id="bib8">
        <label>8</label>
        <element-citation publication-type="journal" id="sbref80">
          <person-group person-group-type="author">
            <name>
              <surname>Wisniewska</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Siwinska</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Felczak</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wielkoszynski</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Krawczynski</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Latos-Bielenska</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>A new case of DOOR syndrome</article-title>
          <source>J Appl Genet</source>
          <volume>49</volume>
          <year>2008</year>
          <fpage>101</fpage>
          <lpage>103</lpage>
          <pub-id pub-id-type="pmid">18263975</pub-id>
        </element-citation>
      </ref>
      <ref id="bib9">
        <label>9</label>
        <element-citation publication-type="journal" id="sbref90">
          <person-group person-group-type="author">
            <name>
              <surname>van Bever</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Balemans</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Duval</surname>
              <given-names>EL</given-names>
            </name>
          </person-group>
          <article-title>Exclusion of OGDH and BMP4 as candidate genes in two siblings with autosomal recessive DOOR syndrome</article-title>
          <source>Am J Med Genet A</source>
          <volume>143</volume>
          <year>2007</year>
          <fpage>763</fpage>
          <lpage>767</lpage>
          <pub-id pub-id-type="pmid">17343268</pub-id>
        </element-citation>
      </ref>
      <ref id="bib10">
        <label>10</label>
        <element-citation publication-type="journal" id="sbref100">
          <person-group person-group-type="author">
            <name>
              <surname>Helbig</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Lowenstein</surname>
              <given-names>DH</given-names>
            </name>
          </person-group>
          <article-title>Genetics of the epilepsies: where are we and where are we going?</article-title>
          <source>Curr Opin Neurol</source>
          <volume>26</volume>
          <year>2013</year>
          <fpage>179</fpage>
          <lpage>185</lpage>
          <pub-id pub-id-type="pmid">23429546</pub-id>
        </element-citation>
      </ref>
      <ref id="bib11">
        <label>11</label>
        <element-citation publication-type="journal" id="sbref110">
          <person-group person-group-type="author">
            <name>
              <surname>Marini</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Conti</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Mei</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>PRRT2 mutations in familial infantile seizures, paroxysmal dyskinesia, and hemiplegic migraine</article-title>
          <source>Neurology</source>
          <volume>79</volume>
          <year>2012</year>
          <fpage>2109</fpage>
          <lpage>2114</lpage>
          <pub-id pub-id-type="pmid">23077026</pub-id>
        </element-citation>
      </ref>
      <ref id="bib12">
        <label>12</label>
        <element-citation publication-type="journal" id="sbref120">
          <person-group person-group-type="author">
            <name>
              <surname>Scheffer</surname>
              <given-names>IE</given-names>
            </name>
            <name>
              <surname>Grinton</surname>
              <given-names>BE</given-names>
            </name>
            <name>
              <surname>Heron</surname>
              <given-names>SE</given-names>
            </name>
          </person-group>
          <article-title>PRRT2 phenotypic spectrum includes sporadic and fever-related infantile seizures</article-title>
          <source>Neurology</source>
          <volume>79</volume>
          <year>2012</year>
          <fpage>2104</fpage>
          <lpage>2108</lpage>
          <pub-id pub-id-type="pmid">23077018</pub-id>
        </element-citation>
      </ref>
      <ref id="bib13">
        <label>13</label>
        <element-citation publication-type="journal" id="sbref130">
          <person-group person-group-type="author">
            <name>
              <surname>Ishida</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Picard</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Rudolf</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Mutations of DEPDC5 cause autosomal dominant focal epilepsies</article-title>
          <source>Nat Genet</source>
          <volume>45</volume>
          <year>2013</year>
          <fpage>552</fpage>
          <lpage>555</lpage>
          <pub-id pub-id-type="pmid">23542701</pub-id>
        </element-citation>
      </ref>
      <ref id="bib14">
        <label>14</label>
        <element-citation publication-type="journal" id="sbref140">
          <person-group person-group-type="author">
            <name>
              <surname>Dibbens</surname>
              <given-names>LM</given-names>
            </name>
            <name>
              <surname>de Vries</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Donatello</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Mutations in DEPDC5 cause familial focal epilepsy with variable foci</article-title>
          <source>Nat Genet</source>
          <volume>45</volume>
          <year>2013</year>
          <fpage>546</fpage>
          <lpage>551</lpage>
          <pub-id pub-id-type="pmid">23542697</pub-id>
        </element-citation>
      </ref>
      <ref id="bib15">
        <label>15</label>
        <element-citation publication-type="journal" id="sbref150">
          <person-group person-group-type="author">
            <name>
              <surname>Nothnagel</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Herrmann</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wolf</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Technology-specific error signatures in the 1000 Genomes Project data</article-title>
          <source>Hum Genet</source>
          <volume>130</volume>
          <year>2011</year>
          <fpage>505</fpage>
          <lpage>516</lpage>
          <pub-id pub-id-type="pmid">21344269</pub-id>
        </element-citation>
      </ref>
      <ref id="bib16">
        <label>16</label>
        <element-citation publication-type="journal" id="sbref160">
          <person-group person-group-type="author">
            <name>
              <surname>Burrage</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>DS</given-names>
            </name>
          </person-group>
          <article-title>Early childhood presentation of Czech dysplasia</article-title>
          <source>Clin Dysmorphol</source>
          <volume>22</volume>
          <year>2013</year>
          <fpage>76</fpage>
          <lpage>80</lpage>
          <pub-id pub-id-type="pmid">23448908</pub-id>
        </element-citation>
      </ref>
      <ref id="bib17">
        <label>17</label>
        <element-citation publication-type="journal" id="sbref170">
          <person-group person-group-type="author">
            <name>
              <surname>Shapiro</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Lietman</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Grover</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Phenotypic variability of osteogenesis imperfecta type V caused by an IFITM5 mutation</article-title>
          <source>J Bone Miner Res</source>
          <volume>28</volume>
          <year>2013</year>
          <fpage>1523</fpage>
          <lpage>1530</lpage>
          <pub-id pub-id-type="pmid">23408678</pub-id>
        </element-citation>
      </ref>
      <ref id="bib18">
        <label>18</label>
        <element-citation publication-type="journal" id="sbref180">
          <person-group person-group-type="author">
            <name>
              <surname>Campeau</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Sule</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Whole-exome sequencing identifies mutations in the nucleoside transporter gene SLC29A3 in dysosteosclerosis, a form of osteopetrosis</article-title>
          <source>Hum Mol Genet</source>
          <volume>21</volume>
          <year>2012</year>
          <fpage>4904</fpage>
          <lpage>4909</lpage>
          <pub-id pub-id-type="pmid">22875837</pub-id>
        </element-citation>
      </ref>
      <ref id="bib19">
        <label>19</label>
        <element-citation publication-type="journal" id="sbref190">
          <person-group person-group-type="author">
            <name>
              <surname>Campeau</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>JT</given-names>
            </name>
          </person-group>
          <article-title>Mutations in KAT6B, encoding a histone acetyltransferase, cause genitopatellar syndrome</article-title>
          <source>Am J Hum Genet</source>
          <volume>90</volume>
          <year>2012</year>
          <fpage>282</fpage>
          <lpage>289</lpage>
          <pub-id pub-id-type="pmid">22265014</pub-id>
        </element-citation>
      </ref>
      <ref id="bib20">
        <label>20</label>
        <element-citation publication-type="journal" id="sbref200">
          <person-group person-group-type="author">
            <name>
              <surname>Sule</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Campeau</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>VW</given-names>
            </name>
          </person-group>
          <article-title>Next-generation sequencing for disorders of low and high bone mineral density</article-title>
          <source>Osteoporos Int</source>
          <volume>24</volume>
          <year>2013</year>
          <fpage>2253</fpage>
          <lpage>2259</lpage>
          <pub-id pub-id-type="pmid">23443412</pub-id>
        </element-citation>
      </ref>
      <ref id="bib21">
        <label>21</label>
        <element-citation publication-type="journal" id="sbref210">
          <person-group person-group-type="author">
            <name>
              <surname>Kelley</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Sternberg</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
          <article-title>Protein structure prediction on the Web: a case study using the Phyre server</article-title>
          <source>Nat Protoc</source>
          <volume>4</volume>
          <year>2009</year>
          <fpage>363</fpage>
          <lpage>371</lpage>
          <pub-id pub-id-type="pmid">19247286</pub-id>
        </element-citation>
      </ref>
      <ref id="bib22">
        <label>22</label>
        <element-citation publication-type="journal" id="sbref220">
          <person-group person-group-type="author">
            <name>
              <surname>Blaise</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Alsarraf</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
          <article-title>Crystal structure of the TLDc domain of oxidation resistance protein 2 from zebrafish</article-title>
          <source>Proteins</source>
          <volume>80</volume>
          <year>2012</year>
          <fpage>1694</fpage>
          <lpage>1698</lpage>
          <pub-id pub-id-type="pmid">22434723</pub-id>
        </element-citation>
      </ref>
      <ref id="bib23">
        <label>23</label>
        <element-citation publication-type="journal" id="sbref230">
          <person-group person-group-type="author">
            <name>
              <surname>Afawi</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Mandelstam</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Korczyn</surname>
              <given-names>AD</given-names>
            </name>
          </person-group>
          <article-title>TBC1D24 mutation associated with focal epilepsy, cognitive impairment and a distinctive cerebro-cerebellar malformation</article-title>
          <source>Epilepsy Res</source>
          <volume>105</volume>
          <year>2013</year>
          <fpage>240</fpage>
          <lpage>244</lpage>
          <pub-id pub-id-type="pmid">23517570</pub-id>
        </element-citation>
      </ref>
      <ref id="bib24">
        <label>24</label>
        <element-citation publication-type="journal" id="sbref240">
          <person-group person-group-type="author">
            <name>
              <surname>Corbett</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Bahlo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jolly</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>A focal epilepsy and intellectual disability syndrome is due to a mutation in TBC1D24</article-title>
          <source>Am J Hum Genet</source>
          <volume>87</volume>
          <year>2010</year>
          <fpage>371</fpage>
          <lpage>375</lpage>
          <pub-id pub-id-type="pmid">20797691</pub-id>
        </element-citation>
      </ref>
      <ref id="bib25">
        <label>25</label>
        <element-citation publication-type="journal" id="sbref250">
          <person-group person-group-type="author">
            <name>
              <surname>Falace</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Filipello</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>La Padula</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>TBC1D24, an ARF6-interacting protein, is mutated in familial infantile myoclonic epilepsy</article-title>
          <source>Am J Hum Genet</source>
          <volume>87</volume>
          <year>2010</year>
          <fpage>365</fpage>
          <lpage>370</lpage>
          <pub-id pub-id-type="pmid">20727515</pub-id>
        </element-citation>
      </ref>
      <ref id="bib26">
        <label>26</label>
        <element-citation publication-type="journal" id="sbref260">
          <person-group person-group-type="author">
            <name>
              <surname>Milh</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Falace</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Villeneuve</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Novel compound heterozygous mutations in TBC1D24 cause familial malignant migrating partial seizures of infancy</article-title>
          <source>Hum Mutat</source>
          <volume>34</volume>
          <year>2013</year>
          <fpage>869</fpage>
          <lpage>872</lpage>
          <pub-id pub-id-type="pmid">23526554</pub-id>
        </element-citation>
      </ref>
      <ref id="bib27">
        <label>27</label>
        <element-citation publication-type="journal" id="sbref270">
          <person-group person-group-type="author">
            <name>
              <surname>Guven</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tolun</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>TBC1D24 truncating mutation resulting in severe neurodegeneration</article-title>
          <source>J Med Genet</source>
          <volume>50</volume>
          <year>2013</year>
          <fpage>199</fpage>
          <lpage>202</lpage>
          <pub-id pub-id-type="pmid">23343562</pub-id>
        </element-citation>
      </ref>
      <ref id="bib28">
        <label>28</label>
        <element-citation publication-type="journal" id="sbref280">
          <person-group person-group-type="author">
            <name>
              <surname>Huang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wilkinson</surname>
              <given-names>MF</given-names>
            </name>
          </person-group>
          <article-title>Regulation of nonsense-mediated mRNA decay</article-title>
          <source>Wiley Interdiscip Rev RNA</source>
          <volume>3</volume>
          <year>2012</year>
          <fpage>807</fpage>
          <lpage>828</lpage>
          <pub-id pub-id-type="pmid">23027648</pub-id>
        </element-citation>
      </ref>
      <ref id="bib29">
        <label>29</label>
        <element-citation publication-type="journal" id="sbref290">
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Macleod</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Su</surname>
              <given-names>AI</given-names>
            </name>
          </person-group>
          <article-title>BioGPS and MyGene.info: organizing online, gene-centric information</article-title>
          <source>Nucleic Acids Res</source>
          <volume>41</volume>
          <year>2013</year>
          <fpage>D561</fpage>
          <lpage>D565</lpage>
          <pub-id pub-id-type="pmid">23175613</pub-id>
        </element-citation>
      </ref>
      <ref id="bib30">
        <label>30</label>
        <element-citation publication-type="journal" id="sbref300">
          <person-group person-group-type="author">
            <name>
              <surname>Lattin</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Schroder</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Su</surname>
              <given-names>AI</given-names>
            </name>
          </person-group>
          <article-title>Expression analysis of G protein-coupled receptors in mouse macrophages</article-title>
          <source>Immunome Res</source>
          <volume>4</volume>
          <year>2008</year>
          <fpage>5</fpage>
          <pub-id pub-id-type="pmid">18442421</pub-id>
        </element-citation>
      </ref>
      <ref id="bib31">
        <label>31</label>
        <element-citation publication-type="journal" id="sbref310">
          <person-group person-group-type="author">
            <name>
              <surname>Tavyev Asher</surname>
              <given-names>YJ</given-names>
            </name>
            <name>
              <surname>Scaglia</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Molecular bases and clinical spectrum of early infantile epileptic encephalopathies</article-title>
          <source>Eur J Med Genet</source>
          <volume>55</volume>
          <year>2012</year>
          <fpage>299</fpage>
          <lpage>306</lpage>
          <pub-id pub-id-type="pmid">22548976</pub-id>
        </element-citation>
      </ref>
      <ref id="bib32">
        <label>32</label>
        <element-citation publication-type="journal" id="sbref320">
          <person-group person-group-type="author">
            <name>
              <surname>Elliott</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Volkert</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>Stress induction and mitochondrial localization of Oxr1 proteins in yeast and humans</article-title>
          <source>Mol Cell Biol</source>
          <volume>24</volume>
          <year>2004</year>
          <fpage>3180</fpage>
          <lpage>3187</lpage>
          <pub-id pub-id-type="pmid">15060142</pub-id>
        </element-citation>
      </ref>
      <ref id="bib33">
        <label>33</label>
        <element-citation publication-type="journal" id="sbref330">
          <person-group person-group-type="author">
            <name>
              <surname>Murphy</surname>
              <given-names>KC</given-names>
            </name>
            <name>
              <surname>Volkert</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>Structural/functional analysis of the human OXR1 protein: identification of exon 8 as the anti-oxidant encoding function</article-title>
          <source>BMC Mol Biol</source>
          <volume>13</volume>
          <year>2012</year>
          <fpage>26</fpage>
          <pub-id pub-id-type="pmid">22873401</pub-id>
        </element-citation>
      </ref>
      <ref id="bib34">
        <label>34</label>
        <element-citation publication-type="journal" id="sbref340">
          <person-group person-group-type="author">
            <name>
              <surname>Oliver</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Finelli</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Edwards</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Oxr1 is essential for protection against oxidative stress-induced neurodegeneration</article-title>
          <source>PLoS Genet</source>
          <volume>7</volume>
          <year>2011</year>
          <fpage>e1002338</fpage>
          <pub-id pub-id-type="pmid">22028674</pub-id>
        </element-citation>
      </ref>
      <ref id="bib35">
        <label>35</label>
        <element-citation publication-type="journal" id="sbref350">
          <person-group person-group-type="author">
            <name>
              <surname>Sieburth</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ch'ng</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Dybbs</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Systematic analysis of genes required for synapse structure and function</article-title>
          <source>Nature</source>
          <volume>436</volume>
          <year>2005</year>
          <fpage>510</fpage>
          <lpage>517</lpage>
          <pub-id pub-id-type="pmid">16049479</pub-id>
        </element-citation>
      </ref>
      <ref id="bib36">
        <label>36</label>
        <element-citation publication-type="journal" id="sbref360">
          <person-group person-group-type="author">
            <name>
              <surname>Uytterhoeven</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Kuenen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kasprowicz</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Miskiewicz</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Verstreken</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Loss of skywalker reveals synaptic endosomes as sorting stations for synaptic vesicle proteins</article-title>
          <source>Cell</source>
          <volume>145</volume>
          <year>2011</year>
          <fpage>117</fpage>
          <lpage>132</lpage>
          <pub-id pub-id-type="pmid">21458671</pub-id>
        </element-citation>
      </ref>
      <ref id="bib37">
        <label>37</label>
        <element-citation publication-type="journal" id="sbref370">
          <person-group person-group-type="author">
            <name>
              <surname>Pan</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Eathiraj</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Munson</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lambright</surname>
              <given-names>DG</given-names>
            </name>
          </person-group>
          <article-title>TBC-domain GAPs for Rab GTPases accelerate GTP hydrolysis by a dual-finger mechanism</article-title>
          <source>Nature</source>
          <volume>442</volume>
          <year>2006</year>
          <fpage>303</fpage>
          <lpage>306</lpage>
          <pub-id pub-id-type="pmid">16855591</pub-id>
        </element-citation>
      </ref>
      <ref id="bib38">
        <label>38</label>
        <element-citation publication-type="journal" id="sbref380">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Muzny</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Reid</surname>
              <given-names>JG</given-names>
            </name>
          </person-group>
          <article-title>Clinical whole-exome sequencing for the diagnosis of mendelian disorders</article-title>
          <source>N Engl J Med</source>
          <volume>369</volume>
          <year>2013</year>
          <fpage>1502</fpage>
          <lpage>1511</lpage>
          <pub-id pub-id-type="pmid">24088041</pub-id>
        </element-citation>
      </ref>
      <ref id="bib39">
        <label>39</label>
        <element-citation publication-type="journal" id="sbref390">
          <person-group person-group-type="author">
            <name>
              <surname>Yu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>BL</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Exome and whole-genome sequencing as clinical tests: a transformative practice in molecular diagnostics</article-title>
          <source>Clin Chem</source>
          <volume>58</volume>
          <year>2012</year>
          <fpage>1507</fpage>
          <lpage>1509</lpage>
          <pub-id pub-id-type="pmid">23065473</pub-id>
        </element-citation>
      </ref>
      <ref id="bib40">
        <label>40</label>
        <element-citation publication-type="journal" id="sbref400">
          <person-group person-group-type="author">
            <name>
              <surname>Frasa</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Koessmeier</surname>
              <given-names>KT</given-names>
            </name>
            <name>
              <surname>Ahmadian</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Braga</surname>
              <given-names>VM</given-names>
            </name>
          </person-group>
          <article-title>Illuminating the functional and structural repertoire of human TBC/RABGAPs</article-title>
          <source>Nat Rev Mol Cell Biol</source>
          <volume>13</volume>
          <year>2012</year>
          <fpage>67</fpage>
          <lpage>73</lpage>
          <pub-id pub-id-type="pmid">22251903</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <sec id="sec1" sec-type="supplementary-material">
      <title>Supplementary Material</title>
      <p>
        <supplementary-material content-type="local-data" id="ecomp10">
          <caption>
            <title>Supplementary appendix</title>
          </caption>
          <media xlink:href="mmc1.pdf"/>
        </supplementary-material>
      </p>
    </sec>
    <ack id="ceack10">
      <sec>
        <title>Acknowledgments</title>
        <p>We thank David Liu for technical assistance, Alyssa Tran and Dale Kerr for clinical research support, Shalini N Jhangiani for exome sequencing coordination, Sabrina Hong for the representation of the structural model of TBC1D24, and Costin Leu for assistance with exome sequencing statistics. Funding was provided by <funding-source id="GS1">NIH</funding-source> grants PO1 HD22657 (BHL), U54 HG006542 (RAG), and U54 HG003273-09 (RAG); by The Rolanette and Berdon Lawrence Bone Disease Program of Texas (BHL), by the Wellcome Trust (SMS), the Henry Smith Charity (SMS), and Action Medical Research (SMS). This work was supported by the <funding-source id="GS2">BCM Intellectual and Developmental Disabilities Research Center</funding-source> (HD024064) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development. This work was partly undertaken at UCLH/UCL, which received a proportion of funding from the Department of Health's NIHR Biomedical Research Centres funding scheme. PMC is supported by a CIHR clinician-scientist training award and the O'Malley Foundation. JTL is supported by <funding-source id="GS3">Ruth L Kirschstein National Research Service Award</funding-source> F30 MH098571-01. LCB was supported by the <funding-source id="GS4">Medical Genetics Research Fellowship Program</funding-source> NIH/NIGMS NIH T32 GM07526.</p>
      </sec>
    </ack>
    <ack>
      <title>Contributors</title>
      <p>PMC designed the study, did the experiments, analysed the data, and wrote the paper. DK did experiments and analysed the data. JTL, SSB, and JED analysed the exome data. AT did experiments. LCB helped with Sanger sequencing. JW and SWC did SNP array data analysis. RCH collected clinical data. CK made the three-dimensional model representations. RAG supervised exome sequencing. MH, BRP, FS, TMF, JvdE, MW, HK, PR, SN, SA, AMe, LDVN, MLB, IDB, GM, MLM, GMR, MG, EB, AMa, FG, AK, WGN, BK, SB, JCG, and DW contributed patient samples and collected clinical data. BHL and SMS jointly supervised the research and revised the paper.</p>
    </ack>
    <ack>
      <title>Conflicts of interest</title>
      <p>We declare that we have no conflicts of interest.</p>
    </ack>
  </back>
  <floats-group>
    <fig id="fig1">
      <label>Figure 1</label>
      <caption>
        <p>Study profile</p>
        <p>DOORS=deafness, onychodystrophy, osteodystrophy, mental retardation, and seizures. DDOD=dominant deafness-onychodystrophy.</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
    <fig id="fig2">
      <label>Figure 2</label>
      <caption>
        <p>Physical features of participants with <italic>TBC1D24</italic> mutations</p>
        <p>(AâF) Some individuals have a wide base of the nose and bulbous end of the nose (individual numbers from tables corresponding to each panel: A=3, B=6, C=5a, D=2b, E=2a, F=7). (GâL) Hands in individuals with <italic>TBC1D24</italic> mutations have triphalangeal thumbs, brachydactyly, short terminal phalanges, and hypoplasia or aplasia of the nails (G=3, H=6, I=5a, J=2b, K=2a, I=7). (MâO) Feet with short terminal phalanges and hypoplasia or aplasia of the nails (M=3, N=6, O=5a). (PâS) Radiographs of the hands in individuals with <italic>TBC1D24</italic> mutations. Note the triphalangeal thumbs and the short terminal phalanges (P=4, Q=5a, R=6, S=1). (T,U) Radiographs of the feet in individuals with <italic>TBC1D24</italic> mutations, showing short terminal phalanges (T=6, U=5a).</p>
      </caption>
      <graphic xlink:href="gr2"/>
    </fig>
    <fig id="fig3">
      <label>Figure 3</label>
      <caption>
        <p>Mutations in <italic>TBC1D24</italic></p>
        <p>(A) Location of the mutations identified in DOORS syndrome and in other epilepsy syndromes. Phe251Leu (blue; homozygous mutation, affecting four siblings) causes focal epilepsy, dysarthria, intellectual disability, cortical thickening, cerebellar atrophy.<xref rid="bib23 bib24" ref-type="bibr"><sup>23,24</sup></xref> Asp147His and Ala515Val (red; compound heterozygous mutation, affecting seven individuals in one family) causes familial infantile myoclonic epilepsy.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> Ser324Thrfs*3 (purple; homozygous mutation, affecting five individuals in one family) causes myoclonic epilepsy, dystonia, hemiparesis, autonomic signs, lethargy, progressive diffuse cerebral atrophy.<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref> Phe229Ser and Cys156* (green; compound heterozygous mutation affecting two siblings)âcauses familial malignant migrating partial seizures of infancy, progressive diffuse cerebral atrophy.<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> The diagram also shows the exonic structure of <italic>TBC1D24,</italic> with the introns not drawn to scale. (B) Real-time PCR of <italic>TBC1D24</italic> in fibroblasts from the individual with a frameshift deletion and a splicing mutation, showing substantial reduction of <italic>TBC1D24</italic> mRNA in affected fibroblasts. (C) Western blot analysis of the cells used in panel B, showing that TBC1D24 protein is undetectable by this method in affected fibroblasts. (D) Structural model of TBC1D24 with the TBC domain coloured in blue and the TBC, LysM, Domain catalytic (TLDc) domain coloured in grey. The N terminal and C termini are labelled, and the red spheres show the alpha carbon atoms of the residues aligning with the arginine and glutamine fingers interacting with the GTP of Rab proteins in other TBC proteins,<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref> based on the structure of Gyp1p in complex with Rab33.<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> The carbon atoms of residues substituted in DOORS syndrome are shown with purple spheres and those substituted in other epilepsy syndromes are shown with black spheres.</p>
      </caption>
      <graphic xlink:href="gr3"/>
    </fig>
    <table-wrap id="tbl1" position="float">
      <label>Table 1</label>
      <caption>
        <p>Mutations identified in <italic>TBC1D24</italic></p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th/>
            <th align="left">
              <bold>Origin</bold>
            </th>
            <th align="left">
              <bold>Maternal allele (DNA)</bold>
            </th>
            <th align="left">
              <bold>Maternal allele (protein)</bold>
            </th>
            <th align="left">
              <bold>Paternal allele (DNA)</bold>
            </th>
            <th align="left">
              <bold>Paternal allele (protein)</bold>
            </th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left">Individual 1</td>
            <td align="left">Japan</td>
            <td align="left">724CâT</td>
            <td align="left">Arg242Cys</td>
            <td align="left">118CâT</td>
            <td align="left">Arg40Cys</td>
          </tr>
          <tr>
            <td align="left">Individual 2a</td>
            <td align="left">USA</td>
            <td align="left">724CâT</td>
            <td align="left">Arg242Cys</td>
            <td align="left">724CâT</td>
            <td align="left">Arg242Cys</td>
          </tr>
          <tr>
            <td align="left">Individual 2b</td>
            <td align="left">USA</td>
            <td align="left">724CâT</td>
            <td align="left">Arg242Cys</td>
            <td align="left">724CâT</td>
            <td align="left">Arg242Cys</td>
          </tr>
          <tr>
            <td align="left">Individual 3</td>
            <td align="left">Germany</td>
            <td align="left">1008delT</td>
            <td align="left">His336GlnfsTer12<xref rid="tbl1fn1" ref-type="table-fn">*</xref></td>
            <td align="left">1206+5GâA</td>
            <td align="left">Splicing</td>
          </tr>
          <tr>
            <td align="left">Individual 4</td>
            <td align="left">India</td>
            <td align="left">724CâT</td>
            <td align="left">Arg242Cys</td>
            <td align="left">724CâT</td>
            <td align="left">Arg242Cys</td>
          </tr>
          <tr>
            <td align="left">Individual 5a</td>
            <td align="left">Chile</td>
            <td align="left">58CâG</td>
            <td align="left">Gln20Glu</td>
            <td align="left">724CâT</td>
            <td align="left">Arg242Cys</td>
          </tr>
          <tr>
            <td align="left">Individual 5b</td>
            <td align="left">Chile</td>
            <td align="left">58CâG</td>
            <td align="left">Gln20Glu</td>
            <td align="left">724CâT</td>
            <td align="left">Arg242Cys</td>
          </tr>
          <tr>
            <td align="left">Individual 6</td>
            <td align="left">France</td>
            <td align="left">1008delT</td>
            <td align="left">His336GlnfsTer12<xref rid="tbl1fn1" ref-type="table-fn">*</xref></td>
            <td align="left">Not identified</td>
            <td align="left">Not identified</td>
          </tr>
          <tr>
            <td align="left">Individual 7</td>
            <td align="left">Brazil</td>
            <td align="left">724CâT</td>
            <td align="left">Arg242Cys</td>
            <td align="left">724CâT</td>
            <td align="left">Arg242Cys</td>
          </tr>
          <tr>
            <td align="left">Individual 8</td>
            <td align="left">Turkey</td>
            <td align="left">119GâT</td>
            <td align="left">Arg40Leu</td>
            <td align="left">119GâT</td>
            <td align="left">Arg40Leu</td>
          </tr>
          <tr>
            <td align="left">Individual 9</td>
            <td align="left">UK</td>
            <td align="left">328GâA</td>
            <td align="left">Gly110Ser</td>
            <td align="left">999GâT</td>
            <td align="left">Leu333Phe</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>Individuals with letters a and b after the number are siblingsÂ·</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tbl1fn1">
          <label>*</label>
          <p>The histidine (His) at position 336 is replaced by a glutamine (Gln), which is followed by a frameshifted protein sequence (fs) ending with a termination codon (Ter) after 12 aminoacids.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="tbl2" position="float">
      <label>Table 2</label>
      <caption>
        <p>Clinical features of patients with DOORS with the <italic>TBC1D24</italic> mutations</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th/>
            <th align="left">
              <bold>Origin</bold>
            </th>
            <th align="left">
              <bold>Age in March, 2013</bold>
            </th>
            <th align="left">
              <bold>Sex</bold>
            </th>
            <th align="left">
              <bold>Consanguinity</bold>
            </th>
            <th align="left">
              <bold>Abnormal finger nails</bold>
            </th>
            <th align="left">
              <bold>Abnormal fingers</bold>
            </th>
            <th align="left">
              <bold>Triphalangeal thumb</bold>
            </th>
            <th align="left">
              <bold>Abnormal toenails</bold>
            </th>
            <th align="left">
              <bold>Abnormal toes</bold>
            </th>
            <th align="left">
              <bold>Developmental delay or intellectual disability</bold>
            </th>
            <th align="left">
              <bold>Feeding difficulties</bold>
            </th>
            <th align="left">
              <bold>Deafness</bold>
            </th>
            <th align="left">
              <bold>Urine 2-oxoglutaric acid</bold>
            </th>
            <th align="left">
              <bold>Seizures</bold>
            </th>
            <th align="left">
              <bold>Age of seizure onset and pharmacoresponsiveness</bold>
            </th>
            <th align="left">
              <bold>Brain imaging</bold>
            </th>
            <th align="left">
              <bold>Cranial shape anomalies</bold>
            </th>
            <th align="left">
              <bold>Growth parameters (percentiles)</bold>
            </th>
            <th align="left">
              <bold>Other findings and reference if published</bold>
            </th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left">1</td>
            <td align="left">Japan</td>
            <td align="left">21 years</td>
            <td align="left">M</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Normal</td>
            <td align="left">Absence, GTCS</td>
            <td align="left">2 months, moderate control with valproic acid, zonisamide, clonazepam, carbamazepine</td>
            <td align="left">Thin cerebellar cortex, hyperintense on T2-imaging, myelination delay</td>
            <td align="left">N</td>
            <td align="left">At 11 years: height 135 cm (10th), weight 31 kg (20th), head 52Â·5 cm (25th)</td>
            <td align="left">Autism spectrum disorder<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref></td>
          </tr>
          <tr>
            <td align="left">2a</td>
            <td align="left">USA</td>
            <td align="left">15 years</td>
            <td align="left">M</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Increased</td>
            <td align="left">Complex partial</td>
            <td align="left">6 months, good control with topiramate, lamotrigine, lacosamide</td>
            <td align="left">Normal MRI</td>
            <td align="left">Sagittal craniosynostosis</td>
            <td align="left">At 14 years: height 154 cm (10th), weight 51 kg (50th), head 54Â·5 cm (40th)</td>
            <td align="left">Large central incisors, widely spaced teeth, delayed eruption of permanent teeth, calcaneal deformity, myopia</td>
          </tr>
          <tr>
            <td align="left">2b</td>
            <td align="left">USA</td>
            <td align="left">8 years</td>
            <td align="left">M</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Increased</td>
            <td align="left">Complex partial</td>
            <td align="left">4 months, good control with topiramate, clorazepate, lacosamide</td>
            <td align="left">Punctate foci of increased T2 signal in right frontal region Increased FLAIR signal around occipital horn</td>
            <td align="left">N</td>
            <td align="left">At 7 years: height 111 cm (2nd), weight 35 kg (98th), head 52 cm (25th)</td>
            <td align="left">Double outlet right ventricle, myopia</td>
          </tr>
          <tr>
            <td align="left">3</td>
            <td align="left">Germany</td>
            <td align="left">2Â·5 years</td>
            <td align="left">F</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Increased</td>
            <td align="left">Focal, secondarily GTCS</td>
            <td align="left">6 weeks, poor control, at least 12 AED tried<xref rid="tbl2fn1" ref-type="table-fn">*</xref></td>
            <td align="left">Delayed myelination</td>
            <td align="left">N</td>
            <td align="left">At 13 months: length 82 cm (97th), weight 12 kg (80th), head 42Â·5 cm (&lt;3rd)</td>
            <td align="left">Microcephaly, nephrocalcinosis, myopia</td>
          </tr>
          <tr>
            <td align="left">4</td>
            <td align="left">India</td>
            <td align="left">3Â·5 years</td>
            <td align="left">M</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Increased</td>
            <td align="left">Focal clonic</td>
            <td align="left">5 months, good control with valproate and topiramate</td>
            <td align="left">Normal MRI</td>
            <td align="left">N</td>
            <td align="left">At 14 months: height 65 cm (&lt;3rd), weight 6 kg (&lt;3rd), head 43Â·5 cm (&lt;3rd)</td>
            <td align="left">Symmetrical growth retardation<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref></td>
          </tr>
          <tr>
            <td align="left">5a</td>
            <td align="left">Chile</td>
            <td align="left">9 years</td>
            <td align="left">M</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Normal</td>
            <td align="left">Complex partial</td>
            <td align="left">3 months, good control with phenobarbital and clobazam</td>
            <td align="left">Normal MRI</td>
            <td align="left">Brachycephaly</td>
            <td align="left">At 6 years 8 months: height 120 cm (50th), weight 25 kg (75th), head 53 cm (75th)</td>
            <td align="left">Widely spaced teeth</td>
          </tr>
          <tr>
            <td align="left">5b</td>
            <td align="left">Chile</td>
            <td align="left">1 years</td>
            <td align="left">M</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Normal</td>
            <td align="left">Complex partial</td>
            <td align="left">N/A</td>
            <td align="left">Normal MRI</td>
            <td align="left">N</td>
            <td align="left">At birth: length 49 cm (35th), weight 3 kg (20th), head 33Â·5 cm (15th)</td>
            <td align="left">None</td>
          </tr>
          <tr>
            <td align="left">6</td>
            <td align="left">France</td>
            <td align="left">1 years</td>
            <td align="left">F</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Increased</td>
            <td align="left">GTCS, focal clonic</td>
            <td align="left">3 months, moderate control with clonazepam, valproic acid, topiramate</td>
            <td align="left">Normal MRI</td>
            <td align="left">N</td>
            <td align="left">At 2 years 2 months: length 85 cm (25th), weight 10Â·7 kg (10th), head 44 cm (&lt;3rd)</td>
            <td align="left">
              <list list-type="simple">
                <list-item id="celistitem10">
                  <p>Microcephaly.</p>
                </list-item>
                <list-item id="celistitem20">
                  <p>Mother had absence seizures as a child</p>
                </list-item>
              </list>
            </td>
          </tr>
          <tr>
            <td align="left">7</td>
            <td align="left">Brazil</td>
            <td align="left">22 years</td>
            <td align="left">M</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Normal</td>
            <td align="left">Infantile spasms, absence, GTCS</td>
            <td align="left">7 months, good control with carbamazepine and clobazam</td>
            <td align="left">Hyperintense T2 signals in the cerebellar hemispheres, especially on the left</td>
            <td align="left">N</td>
            <td align="left">At 22 years: height 170 cm (25th), weight 64 kg (25th), head 54 cm (5th)</td>
            <td align="left">Hypothyroidism</td>
          </tr>
          <tr>
            <td align="left">8a</td>
            <td align="left">Turkey</td>
            <td align="left">Died at 6 months</td>
            <td align="left">F</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">N/A</td>
            <td align="left">Myoclonic, complex partial</td>
            <td align="left">2 months, moderate control with phenobarbital</td>
            <td align="left">Normal cranial ultrasound after birth</td>
            <td align="left">Prominent occiput, frontal bossing, bitemporal narrowing</td>
            <td align="left">At 3Â·5 months: height 59 cm (25th), weight 5Â·2 kg (20th), head 40Â·7 cm (50th)</td>
            <td align="left">
              <list list-type="simple">
                <list-item id="celistitem30">
                  <p>Capillary haemangioma, broad tip of the nose Narrow palate, broad alveolar ridge, short frenulum</p>
                </list-item>
                <list-item id="celistitem40">
                  <p>Died after an epileptic attack</p>
                </list-item>
              </list>
            </td>
          </tr>
          <tr>
            <td align="left">8b</td>
            <td align="left">Turkey</td>
            <td align="left">Died at 9 months</td>
            <td align="left">M</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">N/A</td>
            <td align="left">Myoclonic</td>
            <td align="left">2 months, moderate control with clonazepam, phenytoin, valproic acid, phenobarbital, diazepam</td>
            <td align="left">Initial MRI normal, subdural effusion and cortical atrophy at 4 months</td>
            <td align="left">N</td>
            <td align="left">At 4Â·5 months: height 63 cm (30th), weight 7 kg (50th), head 42 cm (30th)</td>
            <td align="left">
              <list list-type="simple">
                <list-item id="celistitem50">
                  <p>Broad tip of the nose, high palate, broad alveolar ridge No response to light</p>
                </list-item>
                <list-item id="celistitem60">
                  <p>Died after an epileptic attack</p>
                </list-item>
              </list>
            </td>
          </tr>
          <tr>
            <td align="left">9</td>
            <td align="left">UK</td>
            <td align="left">2Â·5 years</td>
            <td align="left">M</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Increased</td>
            <td align="left">GTCS, multifocal myoclonic jerks</td>
            <td align="left">9 weeks, moderate control with valproic acid and levetiracetam</td>
            <td align="left">Normal MRI</td>
            <td align="left">Asymmetric brachycephaly</td>
            <td align="left">At 7 months: height N/A, weight 7Â·6 kg (15th), head 43Â·2 cm (15th)</td>
            <td align="left">Left kidney hydronephrosis, high arched palate</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>Patients listed by each individual's unqiue identifier. N/A=not available. Y=yes. N=no. M=male. F=female. ASD=atrial septal defect. GTCS=generalised tonic-clonic seizures. Head=head circumference. Individuals with letters a and b after the number are siblings. Recent cognitive or developmental assessments were not available for most individuals, but the global development was estimated for individual 8a as that of a 6-week-old baby when she was 12 weeks old, for individual 5a as that of a 1-year-old boy when he was 3 years old, and individual 1 had a developmental quotient of 55 with autism spectrum disorder when he was 4 years old. Hearing loss was qualified as profound sensorineural hearing loss in individuals 1, 2b, 3, 4, and 6. Cochlear implants have been beneficial in individual 3.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tbl2fn1">
          <label>*</label>
          <p>Antiepileptic drugs used or tried with limited success in individual 3 include oxcarbazepine, clobazam, levetiracetam, valproic acid, lamotrigine, sulthiame, diazepam, clonazepam, midazolam, zonisamide, and cortisone pulses. In family 8, DNA was not available from individual 8b, only for 8a and parents. Sensorineural hearing loss was unilateral in individual 12a; in individual 15, it was severe on the right and moderate on the left.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="tbl3" position="float">
      <label>Table 3</label>
      <caption>
        <p>Clinical features of patients with DOORS without the <italic>TBC1D24</italic> mutations</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th/>
            <th align="left">
              <bold>Origin</bold>
            </th>
            <th align="left">
              <bold>Age in March, 2013</bold>
            </th>
            <th align="left">
              <bold>Sex</bold>
            </th>
            <th align="left">
              <bold>Consanguinity</bold>
            </th>
            <th align="left">
              <bold>Abnormal finger nails</bold>
            </th>
            <th align="left">
              <bold>Abnormal fingers</bold>
            </th>
            <th align="left">
              <bold>Triphalangeal thumb</bold>
            </th>
            <th align="left">
              <bold>Abnormal toe nails</bold>
            </th>
            <th align="left">
              <bold>Abnormal toes</bold>
            </th>
            <th align="left">
              <bold>Developmental delay or intellectual disability</bold>
            </th>
            <th align="left">
              <bold>Feeding difficulties</bold>
            </th>
            <th align="left">
              <bold>Deafness</bold>
            </th>
            <th align="left">
              <bold>Urine 2-oxoglutaric acid</bold>
            </th>
            <th align="left">
              <bold>Seizures</bold>
            </th>
            <th align="left">
              <bold>Age of seizure onset and pharmacoresponsiveness</bold>
            </th>
            <th align="left">
              <bold>Brain imaging</bold>
            </th>
            <th align="left">
              <bold>Cranial shape anomalies</bold>
            </th>
            <th align="left">
              <bold>Growth parameters (percentiles)</bold>
            </th>
            <th align="left">
              <bold>Other findings and reference if published</bold>
            </th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left">10</td>
            <td align="left">USA</td>
            <td align="left">4years</td>
            <td align="left">F</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Increased</td>
            <td align="left">GTCS, complex partial</td>
            <td align="left">8 months, good control with leviteracetam</td>
            <td align="left">Delayed myelination in newborn period, normal at 3 years</td>
            <td align="left">N</td>
            <td align="left">At 4 years: height 84 cm (&lt;3rd), weight 10Â·9 kg (&lt;3rd)</td>
            <td align="left">Coloboma left retina, coarctation of the aorta, hip dysplasia, tethered cord, sacral dimple, small and low-set ears, wide nasal bridge, slow hair growth</td>
          </tr>
          <tr>
            <td align="left">11</td>
            <td align="left">Brazil</td>
            <td align="left">12years</td>
            <td align="left">M</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Increased</td>
            <td align="left">No seizures</td>
            <td align="left">N/A</td>
            <td align="left">Dolichocephaly</td>
            <td align="left">N</td>
            <td align="left">At 12 years: height 145 cm (25th), weight 44Â·8 kg (65th), head 54Â·5 cm (60th)</td>
            <td align="left">Micrognathia, bilateral epicanthal folds, anteverted nares, high-arched palate</td>
          </tr>
          <tr>
            <td align="left">12a</td>
            <td align="left">Belgium</td>
            <td align="left">Died at 3 years</td>
            <td align="left">F</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Increased</td>
            <td align="left">GTCS</td>
            <td align="left">3 months, resistant to treatment</td>
            <td align="left">Hyperintensities in the pons</td>
            <td align="left">Metopic ridge, biparietal narrowing</td>
            <td align="left">At 3 months: height 3rd, weight 3rd, head 10â25th</td>
            <td align="left">
              <list list-type="simple">
                <list-item id="celistitem70">
                  <p>Metopic ridge, biparietal narrowing, unilateral hearing loss</p>
                </list-item>
                <list-item id="celistitem80">
                  <p>Short fixation, abnormal eye movements, and intermittent strabismus, aspiration pneumonias, dysplastic ears<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref></p>
                </list-item>
              </list>
            </td>
          </tr>
          <tr>
            <td align="left">12b</td>
            <td align="left">Belgium</td>
            <td align="left">5years</td>
            <td align="left">M</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Increased</td>
            <td align="left">Myoclonic</td>
            <td align="left">3 weeks, poor control</td>
            <td align="left">Thin corpus callosum</td>
            <td align="left">N</td>
            <td align="left">At birth, normal growth parameters</td>
            <td align="left">
              <list list-type="simple">
                <list-item id="celistitem90">
                  <p>At 2 months, VEP showed a weak response, and ERG was normal.</p>
                </list-item>
                <list-item id="celistitem100">
                  <p>Patent ductus arteriosus, dysplastic ears<xref rid="bib9" ref-type="bibr"><sup>9</sup></xref></p>
                </list-item>
              </list>
            </td>
          </tr>
          <tr>
            <td align="left">13</td>
            <td align="left">India</td>
            <td align="left">Died at 3months</td>
            <td align="left">F</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">N</td>
            <td align="left">N/A</td>
            <td align="left">No seizures</td>
            <td align="left">N/A</td>
            <td align="left">N/A</td>
            <td align="left">Broad forehead</td>
            <td align="left">At birth: 2Â·2 kg (&lt;3rd). At 2Â·5 months: head 33 cm (&lt;3rd)</td>
            <td align="left">Microcephaly, progeroid appearance, bilateral low-set ears, dysplastic pinna, high arched palate, macrostomia, submucous clefting of palate, protruding tongue, anteverted nares, long smooth philtrum, hypertrichosis, broad forehead</td>
          </tr>
          <tr>
            <td align="left">14</td>
            <td align="left">Netherlands</td>
            <td align="left">2Â·5years</td>
            <td align="left">F</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">N</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Normal</td>
            <td align="left">No seizures</td>
            <td align="left">N/A</td>
            <td align="left">N/A</td>
            <td align="left">N</td>
            <td align="left">At 10 months: height 69 cm (15th), weight 6Â·6 kg (&lt;3rd), head 42Â·5 cm (5th)</td>
            <td align="left">VSD, long eyelashes, cleft palate, cup-shaped ears</td>
          </tr>
          <tr>
            <td align="left">15</td>
            <td align="left">India</td>
            <td align="left">8years</td>
            <td align="left">F</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">N/A</td>
            <td align="left">Focal motor</td>
            <td align="left">4 years, good control</td>
            <td align="left">Normal MRI</td>
            <td align="left">High forehead</td>
            <td align="left">At 4Â·5 years: height &lt;3rd, weight &lt;3rd, head &lt;3rd</td>
            <td align="left">Microcephaly, horizontal nystagmus</td>
          </tr>
          <tr>
            <td align="left">16</td>
            <td align="left">UK of African origin</td>
            <td align="left">6years</td>
            <td align="left">M</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N/A</td>
            <td align="left">GTCS</td>
            <td align="left">2 years 9 months; good control with valproic acid</td>
            <td align="left">
              <list list-type="simple">
                <list-item id="celistitem110">
                  <p>Partial corpus callosum agenesis</p>
                </list-item>
                <list-item id="celistitem120">
                  <p>Small lesion in right putamen suggestive of a developmental venous anomaly</p>
                </list-item>
              </list>
            </td>
            <td align="left">N</td>
            <td align="left">At 3 years 3 months: weight 15Â·6 kg (65th), height 93Â·1 cm (15th), head 48Â·1 cm (5th)</td>
            <td align="left">
              <list list-type="simple">
                <list-item id="celistitem130">
                  <p>Severe gastro-oesophageal reflux, ASD requiring surgical repair, coarse facial features, low frontal hairline, webbed neck, micrognathia, midline groove of lower lip, thick lips, thickened gingiva, long tongue, anteverted abnormally formed ears</p>
                </list-item>
                <list-item id="celistitem140">
                  <p>Severe kyphoscoliosis (congenital) and calcaneovalgus</p>
                </list-item>
                <list-item id="celistitem150">
                  <p>Tracheomalacia, tracheostomy, multiple keloid scar formation</p>
                </list-item>
              </list>
            </td>
          </tr>
          <tr>
            <td align="left">17</td>
            <td align="left">Lebanon</td>
            <td align="left">1year</td>
            <td align="left">F</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N/A</td>
            <td align="left">No seizures</td>
            <td align="left">N/A</td>
            <td align="left">Aplasia of falx cerebri</td>
            <td align="left">N</td>
            <td align="left">At 11 weeks: length 57 cm (8th), weight 4Â·5 kg (3rd), head 36 cm (&lt;3rd)</td>
            <td align="left">
              <list list-type="simple">
                <list-item id="celistitem160">
                  <p>High frontal and temporal hairline, hypertelorism, upslanting palpebral fissures, broad nose, low-set and posteriorly rotated ears</p>
                </list-item>
                <list-item id="celistitem170">
                  <p>Hypoplastic patellae Uterus bicornis, hypercalcaemia</p>
                </list-item>
              </list>
            </td>
          </tr>
          <tr>
            <td align="left">18</td>
            <td align="left">Iran</td>
            <td align="left">14years</td>
            <td align="left">M</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">N</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">N/A</td>
            <td align="left">GTCS</td>
            <td align="left">1 year, good control with phenobarbital</td>
            <td align="left">N/A</td>
            <td align="left">Brachycephaly</td>
            <td align="left">At 14 years: head 50Â·5 cm (&lt;3rd)</td>
            <td align="left">
              <list list-type="simple">
                <list-item id="celistitem180">
                  <p>Multicystic left kidney, hypertrophic right kidney, cleft palate, bilateral inguinal hernia, short PF, blepharophimosis, microcornea, telecanthus, prominent nose, bilateral narrowing of ear canals, small mouth, malocclusion of teeth, hallux valgus</p>
                </list-item>
                <list-item id="celistitem190">
                  <p>Affected sibling died at 1Â·5 years</p>
                </list-item>
              </list>
            </td>
          </tr>
          <tr>
            <td align="left">19</td>
            <td align="left">USA</td>
            <td align="left">Died at 3weeks</td>
            <td align="left">M</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Normal</td>
            <td align="left">No seizures</td>
            <td align="left">N/A</td>
            <td align="left">Dandy-Walker malformation, agenesis of the corpus callosum</td>
            <td align="left">N</td>
            <td align="left">At birth: length 44 cm (&lt;3rd), weight 2Â·26 kg (&lt;3rd), head 33 cm (17th)</td>
            <td align="left">Blindness, widely spaced nipples, low-set ears</td>
          </tr>
          <tr>
            <td align="left">20</td>
            <td align="left">Canada</td>
            <td align="left">2years</td>
            <td align="left">F</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Normal</td>
            <td align="left">No seizures</td>
            <td align="left">N/A</td>
            <td align="left">Dandy-Walker malformation, small focal area of restricted diffusion in the right posterior basal ganglia area</td>
            <td align="left">Large anterior fontanelle, microcephaly, narrow bifrontal diameter</td>
            <td align="left">At 1 year: height &lt;3rd, weight &lt;3rd, head &lt;3rd</td>
            <td align="left">Sparse fine hair, right optic nerve morning glory anomaly, persistent left superior vena cava draining into the coronary sinus, atrial septal defect, mild tricuspid regurgitation, laryngomalacia, short sternum, right thoracic scoliosis, low conus medullaris, rocker bottom feet, widely spaced nipples, high arched palate, short neck</td>
          </tr>
          <tr>
            <td align="left">21</td>
            <td align="left">Ireland</td>
            <td align="left">Died at 10years</td>
            <td align="left">M</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Normal</td>
            <td align="left">GTCS, absence, myoclonic</td>
            <td align="left">6 months</td>
            <td align="left">Normal MRI</td>
            <td align="left">Dolichocephaly</td>
            <td align="left">At 3 years 6 months: height 110 cm (&gt;97th), weight 19 kg (95th), head 58 cm (&gt;97th)</td>
            <td align="left">Double outlet right ventricle, recurrent chest infections, supernumerary nipple, broad alveolar ridge, blindness, hydronephrosis</td>
          </tr>
          <tr>
            <td align="left">22</td>
            <td align="left">UK of Indian origin</td>
            <td align="left">29years</td>
            <td align="left">F</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Normal</td>
            <td align="left">GTCS, Complex partial, episodes of status epilepticus</td>
            <td align="left">3 months, moderate control with valproate, levetiracetam, pregabalin, phenytoin, topiramate</td>
            <td align="left">Diffuse atrophy cerebrum and cerebellum, asymmetric lateral ventricles</td>
            <td align="left">N</td>
            <td align="left">At 29 years: weight 50 kg (15th)</td>
            <td align="left">Long and thin face, high arched palate</td>
          </tr>
          <tr>
            <td align="left">23</td>
            <td align="left">India</td>
            <td align="left">7years</td>
            <td align="left">M</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">N</td>
            <td align="left">Normal</td>
            <td align="left">GTCS</td>
            <td align="left">11 months, good control with phenytoin and phenobarbital</td>
            <td align="left">Normal MRI</td>
            <td align="left">N</td>
            <td align="left">At 6 years: height 110 cm (15th), weight 18 kg (15th), head 46Â·5 cm (&lt;3rd)</td>
            <td align="left">Delayed permanent dentition, small teeth, cavities, anteverted nares, low-set pinna, open mouth, ASD, sibling with similar phenotype died at 1 year 9 months</td>
          </tr>
          <tr>
            <td align="left">24</td>
            <td align="left">Poland</td>
            <td align="left">22years</td>
            <td align="left">M</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Normal</td>
            <td align="left">No seizures</td>
            <td align="left">N/A</td>
            <td align="left">N/A</td>
            <td align="left">N</td>
            <td align="left">At birth: length 57 cm (&gt;97th), height 3Â·9 kg (75th), head 32 cm (4th)</td>
            <td align="left">Delayed teething, haemangioma, epicanthus of the left eye, ptosis, strabismus, asymmetric face, high-arched palate<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref></td>
          </tr>
          <tr>
            <td align="left">25</td>
            <td align="left">New Zealand</td>
            <td align="left">12years</td>
            <td align="left">M</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Normal</td>
            <td align="left">Infantile spasms</td>
            <td align="left">1 year, good control with vigabatrin</td>
            <td align="left">N/A</td>
            <td align="left">N</td>
            <td align="left">At 7 years: height 188 cm (&gt;97th), weight 24 kg (60th)</td>
            <td align="left">Broad nose, dental misalignment and irregularities, ASD</td>
          </tr>
          <tr>
            <td align="left">26</td>
            <td align="left">UK</td>
            <td align="left">15years</td>
            <td align="left">M</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">Y</td>
            <td align="left">N</td>
            <td align="left">Y</td>
            <td align="left">Normal</td>
            <td align="left">No seizures</td>
            <td align="left">N/A</td>
            <td align="left">N/A</td>
            <td align="left">N</td>
            <td align="left">At 5 months: length 64Â·5 cm (25th), weight 6Â·3 kg (5th), head 44Â·5 cm (75th)</td>
            <td align="left">Premature birth</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>Patients listed by each individual's unqiue identifier. N/A=not available. Y=yes. N=No. M=male. F=female. ASD=atrial septal defect. GTCS=generalised tonic-clonic seizures. Head=head circumference. VEP=Visual evoked potential. VSD=ventricular septal defects. ERG=electroretinogram. PF=palpebral fissures. Individuals with letters a and b after the number are siblings. Recent cognitive or developmental assessments were not available for most individuals. Intellectual disability or developmental delay was categorised as mild for individual 24, moderate for individual 14, and severe for individuals 10, 11, 12a, 12b, 16, 21, 22, 23, and 25. Formal audiometric test results were not available for most individuals. Sensorineural hearing loss was unilateral in individual 12a; in individual 15, it was severe on the right and moderate on the left.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <boxed-text id="box1">
      <label>Panel</label>
      <caption>
        <title>Research in context</title>
      </caption>
      <p>
        <bold>Systematic review</bold>
      </p>
      <p>We searched PubMed and the references of included papers for articles published from Jan 1, 1970, to March 1, 2013. We used the following search terms: âDOOR syndromeâ, âDOORS syndromeâ, âdeafness and onychodystrophyâ, â<italic>TBC1D24</italic>â, â2-oxoglutaric aciduriaâ, â2-oxoglutarateâ, âepilepsyâ, and âexome sequencingâ. We retrieved all previous reports of individuals with DOORS syndrome and assessed the key clinical features, which present in most patients as sensorineural deafness, nail hypoplasia, terminal phalangeal hypoplasia, triphalangeal thumbs, developmental delay, intellectual disability, seizures, craniofacial anomalies, 2-oxoglutaric aciduria, and MRI anomalies. 25% or more of patients have consanguinity or affected siblings, and optic atrophy. Fewer than 25% of patients have congenital heart defects, urinary tract anomalies, and peripheral neuropathy. Genetic testing in the one previous study excluded the candidate genes <italic>BMP4</italic> and <italic>OGDH.</italic></p>
      <p>
        <bold>Interpretation</bold>
      </p>
      <p>Our findings suggest that mutations in <italic>TBC1D24</italic> are a key genetic cause in some individuals with DOORS syndrome, and imply that testing for <italic>TBC1D24</italic> mutations should be considered by clinicians if they suspect a diagnosis of DOORS syndrome. Our findings also substantiate the role of this gene in various epilepsy syndromes, as is seen also with other epilepsy-related genes such as <italic>SCN1A</italic>, <italic>KCNQ2</italic>, and <italic>PRRT2</italic>. Moreover, our findings lend support to the idea of pleiotropy in epilepsy genetics because, although some mutations in <italic>TBC1D24</italic> can cause mild epilepsy without other substantial associated features, other mutations in <italic>TCB1C24</italic> cause epilepsy as part of a syndrome with features beyond the nervous system. Our findings lend support to the idea that the genomic coverage provided by whole-exome sequencing is likely to prove useful in the diagnosis of rare neurological diseases that have clinical and genetic heterogeneity.</p>
    </boxed-text>
  </floats-group>
</article>

</metadata></record></GetRecord></OAI-PMH>